Microcapsules encapsulating water-soluble substances

By using polymers combining polyalkylene glycols and polyhydroxyalkanoates, microcapsules with a total aqueous phase volume of 0.025 cm³/g to 0.25 cm³/g in W/O emulsions were prepared, solving the stability problem of macromolecular drugs and achieving stable encapsulation and sustained release of protein, peptide, and nucleic acid drugs.

CN123076404APending Publication Date: 2026-11-10TORAY INDUSTRIES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202580026989.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-10
Filing Date
2025-04-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

In the prior art, the stability of macromolecular drugs such as peptides, proteins and nucleic acid drugs has not been fully studied, especially when using poly(lactide-co-glycolic acid) copolymers, it is necessary to clarify which polymer properties can provide stable water-soluble formulations.

Method used

Microcapsules were prepared using a polymer with a chemical structure combining polyalkylene glycols and polyhydroxyalkanoates. The total volume of the aqueous phase in the W/O emulsion was determined to be 0.025 cm³/g to 0.25 cm³/g by differential scanning calorimetry. This method was used to improve the stability of macromolecular drugs.

Benefits of technology

It provides formulations of water-soluble substances with excellent stability, which can effectively encapsulate and sustain the release of protein, peptide and nucleic acid drugs, improving their stability and sustained release.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076404A_ABST
    Figure CN123076404A_ABST
Patent Text Reader

Abstract

One object of this disclosure is to provide a formulation of a water-soluble substance comprising a polymer and exhibiting excellent stability. The inventors have discovered that a formulation of a water-soluble substance with excellent stability can be provided by a microcapsule encapsulating the water-soluble substance. The microcapsule comprises a polymer having a chemical structure composed of a polyalkylene glycol and a polyhydroxyalkanoic acid, and the water-soluble substance, wherein, when a W / O emulsion prepared from the polymer according to the following method is measured by differential scanning calorimetry (temperature-increasing method), the total volume of the aqueous phase in the W / O emulsion is 0.025 cm³. 3 / g~0.25cm 3 / g: W / O emulsion preparation method: Dissolve 50 mg of the polymer in 500 μL of 0.5 w / v% sorbitan monooleate / dichloromethane solution, add 100 μL of water, and then irradiate with ultrasound to prepare a W / O emulsion.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to a microcapsule encapsulating a water-soluble substance, a composition containing the microcapsule, and a method for screening a sustained-release polymer. Background Technology

[0002] In recent years, the importance of macromolecular drugs such as peptide drugs, protein drugs, and nucleic acid drugs has been continuously increasing. However, macromolecular drugs are generally less stable than conventional small molecule drugs. Therefore, research has been ongoing on technologies to formulate stable macromolecular drugs.

[0003] For example, PTL 1 attempted to improve the stability of antibody molecules by using dry polymer microspheres loaded with antibody molecules, the polymer microspheres containing antibody molecules, polymers and cyclodextrin, and optionally also containing buffers and / or surfactants.

[0004] List of cited references Patent documents PTL 1: JP2022-533038A PTL 2: WO2018 / 062464 Non-patent literature NPL 1: Kazuhiko Ishikiriyama, Utilization of Thermal Analysis in Polymer Material Development, NetsuSokutei, 46(4):2019.10, pp. 155-162. NPL 2: Masanori IIJIMA, Ryuichi SUGIMOTO, Shinya SAKAI, Topics of Polymer Materials Studied with Differential Scanning Calorimetry, Netsu Sokutei, 36(5): 2009.11, pp. 247-254. Summary of the Invention

[0005] Technical issues However, even when limited to the poly(lactide-co-glycolic acid) copolymer (hereinafter also referred to as "lactic acid / glycolic acid copolymer") used in examples such as PTL 1, the polymer represented by this name includes polymers with diverse structures depending on the polymerization method, molecular weight, etc. Among polymers with diverse structures, the specific polymer properties required to obtain stable formulations containing water-soluble substances such as macromolecular drugs have not been sufficiently studied.

[0006] Therefore, the inventors investigated the specific polymer properties required to impart stability to water-soluble substances in formulations. Specifically, the inventors' main objective is to provide a formulation containing a polymer and exhibiting excellent stability of a water-soluble substance.

[0007] Technical solutions to the problem As a result of the above research, the inventors discovered the following possibility: if microcapsules containing a polymer with a chemical structure combining polyalkylene glycols and polyhydroxyalkanoates and water-soluble substances have the following characteristic, namely, the total volume of the aqueous phase in a W / O emulsion prepared from the polymer by a specified method is 0.025 cm³ as determined by differential scanning calorimetry (temperature-increasing method). 3 / g~0.25cm 3 / g can provide formulations of water-soluble substances with excellent stability. This disclosure was completed after further refinement.

[0008] This disclosure includes, for example, the subjects described in the following items.

[0009] Item 1: Microcapsules contain a polymer having a chemical structure of polyalkylene glycols and polyhydroxyalkanoates, as well as a water-soluble substance; When the polymer was measured by differential scanning calorimetry (temperature-increasing method) on a W / O emulsion prepared according to the following method, the total volume of the aqueous phase in the W / O emulsion was 0.025 cm³. 3 / g~0.25cm 3 / g, 50 mg of the polymer was dissolved in 500 μL of a 0.5 w / v% sorbitan monooleate / dichloromethane solution, 100 μL of water was added, and then the mixture was irradiated with ultrasound to prepare a W / O emulsion.

[0010] Item 2: According to the microcapsule of claim 1, the polyhydroxyalkanoic acid is a homopolymer of monomers selected from lactic acid, glycolic acid and 6-hydroxyhexanoic acid, or a copolymer containing two or more of the monomers described.

[0011] Item 3: The microcapsules according to claim 1 or 2, wherein the polyhydroxyalkanoic acid is a lactic acid / glycolic acid copolymer.

[0012] Item 4: The microcapsules according to any one of claims 1 to 3, wherein the polyalkylene glycol has a chemical structure of a linear polyalkylene glycol combined with a polyol, and each molecule has 3 to 10 terminal hydroxyl groups.

[0013] Item 5: The microcapsules according to any one of claims 1 to 4, wherein the polyalkylene glycol is polyethylene glycol.

[0014] Item 6: The microcapsules according to any one of claims 1 to 5, wherein the polyalkylene glycol is a 4- or 8-branched polyethylene glycol.

[0015] Item 7: The microcapsules according to any one of claims 1 to 6, wherein the polymer has a chemical structure of 4 or 8-branched polyethylene glycol combined with a lactic acid / glycolic acid copolymer.

[0016] Item 8: The microcapsules according to any one of claims 1 to 7, wherein the polyalkylene glycol has a number-average molecular weight of 5,000 to 20,000.

[0017] Item 9: The microcapsules according to any one of claims 1 to 8, wherein the polyhydroxyalkanoic acid has a number-average molecular weight of 10,000 to 70,000.

[0018] Item 10: The microcapsules according to any one of claims 1 to 9, wherein the number-average molecular weight ratio of the polyalkylene glycol to the number-average molecular weight of the polyhydroxyalkanoic acid is 1:1 to 1:6.

[0019] Item 11: The microcapsules according to any one of claims 1 to 10, wherein the polymer has a chemical structure of 4 or 8 branched polyethylene glycol combined with a lactic acid / glycolic acid copolymer.

[0020] The number-average molecular weight of the 4- or 8-branched polyethylene glycol is 5,000 to 20,000. The number-average molecular weight of the lactic acid / glycolic acid copolymer is 10,000 to 70,000, and The ratio of the number-average molecular weight of the polyethylene glycol to the number-average molecular weight of the lactic acid / glycolic acid copolymer is 1:1 to 1:6.

[0021] Item 12: The microcapsule according to any one of claims 1 to 11, wherein the water-soluble substance is selected from at least one of proteins, peptides, and nucleic acids.

[0022] Item 13: A composition comprising microcapsules according to any one of claims 1 to 12.

[0023] Item 14: The composition according to item 13 is in the form of spheres, sheets, needles, rods, or rolls.

[0024] Item 15: The composition according to item 13 or 14 is a sustained-release pharmaceutical composition.

[0025] Item 16: The screening method for sustained-release polymers comprises the following steps (a) to (c). Step (a): The step of preparing a solution of the polymer to be tested by dissolving the polymer to be tested in a solution containing a surfactant and an immiscible organic solvent containing water; Step (b): The step of adding water to the polymer solution to be tested prepared in step (a) and then irradiating it with ultrasound to prepare a W / O emulsion; and Step (c): The total volume of the aqueous phase in the W / O emulsion prepared in step (b) is 0.025 cm³ when measured by differential scanning calorimetry (temperature-increasing method). 3 / g~0.25cm 3 The step of screening sustained-release polymers using / g as an indicator.

[0026] Beneficial effects of the invention The technology disclosed herein enables the provision of formulations of water-soluble substances with excellent stability. Attached Figure Description

[0027] Figure 1 The image shown is a scanning electron microscope (SEM) image (hereinafter sometimes referred to as "SEM") of the microspheres encapsulated with bevacizumab obtained in test 2.1.1 (polymer: 1PEG (2kDa)-PLGA (11.5kDa)). Scale bar = 10 μm.

[0028] Figure 2 SEM images of the microspheres encapsulated with bevacizumab obtained in test 2.1.1 are shown (polymer: 1PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0029] Figure 3SEM images of the microspheres encapsulated with bevacizumab obtained in test 2.1.1 are shown (polymer: 2PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0030] Figure 4 SEM images of the microspheres encapsulated with bevacizumab obtained in test 2.1.1 are shown (polymer: 4PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0031] Figure 5 SEM images of the microspheres encapsulated with bevacizumab obtained in test 2.1.1 are shown (polymer: 4PEG (10 kDa)-PLGA (69 kDa)). Scale bar = 10 μm.

[0032] Figure 6 SEM images of the microspheres encapsulated with bevacizumab obtained in test 2.1.1 are shown (polymer: 4PEG (10kDa)-PLGA (130kDa)). Scale bar = 10 μm.

[0033] Figure 7 SEM images of the microspheres encapsulated with bevacizumab obtained in test 2.1.1 are shown (polymer: 8PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0034] Figure 8 SEM images of the microspheres encapsulating cetuximab obtained in test 2.1.1 are shown (polymer: PLGA (45 kDa)). Scale bar = 10 μm.

[0035] Figure 9 SEM images of the microspheres encapsulated with cetuximab obtained in test 2.1.1 are shown (polymer: 4PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0036] Figure 10 SEM images of the microspheres encapsulated with ranibizumab obtained in test 3.1.1 are shown (polymer: 4PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0037] Figure 11 SEM images of the microspheres encapsulated with fareximab obtained in test 3.2.1 are shown (polymer: 4PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0038] Figure 12SEM images of the microspheres encapsulated with iboxizumab obtained in test 3.3.1 are shown (polymer: 4PEG (10kDa)-PLGA (40kDa)). Scale bar = 10 μm.

[0039] Figure 13 The two-dimensional structure (left) and three-dimensional structure (right) of calcitonin are shown.

[0040] Figure 14 The results of Test 5 are shown. The vertical axis represents the percentage of IgG released (cumulative %), and the horizontal axis represents the time (days) since the start of the release test.

[0041] Figure 15 The results of Test 6 are shown. The vertical axis represents the percentage of nucleic acid released (cumulative %), and the horizontal axis represents the time (days) since the start of the release test.

[0042] Figure 16 The results of Test 7 are shown. The vertical axis represents the percentage of model dye released (cumulative %), and the horizontal axis represents the time (days) since the start of the release test.

[0043] Figure 17 SEM images of the microspheres obtained in test 8.1 are shown.

[0044] Figure 18 The results of test 8.3 are shown. The vertical axis represents the percentage (cumulative %) of siRNA compound 1 released, and the horizontal axis represents the time (weeks) since the start of the release test.

[0045] Figure 19 The results of test 8.4 are shown. The vertical axis represents the activity retention rate (%) of siRNA compound 1, and the horizontal axis represents the time (weeks) since the start of the test. Detailed Implementation

[0046] The various embodiments included in this disclosure are described in more detail below. This disclosure preferably includes, but is not limited to, microcapsules encapsulating water-soluble substances, compositions comprising such microcapsules, and methods for screening sustained-release polymers. This disclosure includes all content disclosed herein and which will be recognized by those skilled in the art.

[0047] The microcapsules included in this disclosure comprise a polymer having a chemical structure composed of polyalkylene glycols and polyhydroxyalkanoates, and a water-soluble substance, wherein, when the W / O emulsion prepared from the polymer according to the following method is measured by differential scanning calorimetry (temperature-increasing method), the total volume of the aqueous phase in the W / O emulsion is 0.025 cm³. 3 / g~0.25cm 3 / g: 50 mg of the polymer was dissolved in 500 μL of a 0.5 w / v % sorbitan monooleate / dichloromethane solution, 100 μL of water was added, and the mixture was then subjected to ultrasonic treatment to prepare a W / O emulsion. Hereinafter, the microcapsules contained in this disclosure are also referred to as "microcapsules of this disclosure".

[0048] A. Polymers disclosed herein As described above, the microcapsules of this disclosure comprise a polymer having a chemical structure composed of polyalkylene glycols and polyhydroxyalkanoates, and a water-soluble substance, wherein, when the W / O emulsion prepared from the polymer according to the following method is measured by differential scanning calorimetry (temperature-increasing method), the total volume of the aqueous phase in the W / O emulsion is 0.025 cm³. 3 / g~0.25cm 3 / g: Dissolve 50 mg of the polymer in 500 μL of a 0.5 w / v% sorbitan monooleate / dichloromethane solution, add 100 μL of water, and then irradiate with ultrasound to prepare a W / O emulsion. This polymer is also referred to as "the polymer of this disclosure". The polymer of this disclosure is described in detail below.

[0049] A-1. Polyalkylene glycol In the present disclosure, the polyalkylene glycol constituting the polymer can be linear or branched. In particular, branched polyalkylene glycols are preferred from the viewpoint of imparting excellent sustained-release properties to water-soluble substances to the microcapsules of the present disclosure.

[0050] As described below, the microcapsules of this disclosure can be provided in the form of a dried product. When the microcapsules of this disclosure are provided in the form of granular dried products such as microspheres, if the polyalkylene glycol constituting the polymer of this disclosure is a branched polyalkylene glycol, the granular dried product can have low adhesiveness (the property of not easily adhering to other particles or container materials) and excellent flowability. Therefore, from the viewpoint of facilitating the handling of granular dried products, the polyalkylene glycol constituting the polymer of this disclosure is preferably a branched polyalkylene glycol.

[0051] When the polyalkylene glycol is a branched polyalkylene glycol, the branched polyalkylene glycol has a structure in which at least a portion of the hydroxyl groups of the polyalkylene glycol and the polyol are bonded by ether bonds. In particular, it is preferred that the branched polyalkylene glycol has a structure in which all the hydroxyl groups of the polyalkylene glycol and the polyol are bonded by ether bonds. It is even more preferred that the branched polyalkylene glycol has a structure in which all the hydroxyl groups of the linear polyalkylene glycol and the polyol are bonded by ether bonds.

[0052] The number of hydroxyl groups in a polyol can be, for example, 2 to 20. The number of hydroxyl groups in a polyol is preferably 2 to 15, more preferably 2 to 10, even more preferably 2 to 8, and particularly preferably 2, 4 or 8.

[0053] Specific examples of polyols include glycerol, polyglycerol, and pentaerythritol; as well as sugars such as glucose, fructose, xylose, galactose, mannose, erythrose, arabinose, sucrose, maltose, lactose, trehalose, and cellobiose. Examples of polyglycerols include dimers to hexamers of glycerol. The upper or lower limit of this range can be 2, 3, 4, 5, or 6. Polyols can also have structures formed by the polymerization of two or more of the polyols mentioned above, such as dipentaerythritol.

[0054] The branched polyalkylene glycol has, for example, 2 to 10 branches per molecule. The upper or lower limit of this range can be 2, 3, 4, 5, 6, 7, 8, 9, or 10. The branched number of the branched polyalkylene glycol can be described as the number of terminal hydroxyl groups possessed by the branched polyalkylene glycol. That is, for example, a 4-branched polyalkylene glycol has 4 terminal hydroxyl groups per molecule. From the viewpoint of being able to stably retain water-soluble substances in the microcapsules of this disclosure, and from the viewpoint of being able to impart excellent sustained-release properties to water-soluble substances to the microcapsules of this disclosure, the branched polyalkylene glycol preferably has 3 to 10 terminal hydroxyl groups per molecule, more preferably 4 to 8 terminal hydroxyl groups per molecule, and particularly preferably 4 or 8 terminal hydroxyl groups per molecule.

[0055] More specifically, examples of polyalkylene glycols constituting the polymers disclosed herein include polyethylene glycol, polypropylene glycol, and polybutanediol. From a biocompatibility perspective, polyethylene glycol is preferred as the polyalkylene glycol constituting the polymers disclosed herein. Generally, alkylene groups with fewer carbon atoms exhibit higher hydrophilicity.

[0056] The number average molecular weight of the polyalkylene glycol constituting the polymer of this disclosure is not particularly limited as long as the effects of this disclosure are achieved, and for example, it can be 1,000 to 50,000. From the viewpoint of being able to stably retain water-soluble substances in the microcapsules of this disclosure, and from the viewpoint of being able to endow the microcapsules of this disclosure with excellent sustained-release properties for water-soluble substances, the number average molecular weight of the polyalkylene glycol constituting the polymer of this disclosure is preferably 1,000 to 30,000, more preferably 5,000 to 20,000, even more preferably 7,000 to 15,000, and particularly preferably 8,000 to 13,000. In particular, when the polyalkylene glycol constituting the polymer of this disclosure is a branched polyalkylene glycol, the number average molecular weight of the branched polyalkylene glycol in the polymer is preferably 3,000 to 30,000, more preferably 5,000 to 20,000, even more preferably 7,000 to 15,000, and particularly preferably 8,000 to 13,000.

[0057] A preferred embodiment of the polyalkylene glycol constituting the polymer of this disclosure is a linear polyethylene glycol with a number average molecular weight of 1,000 to 3,000 in the polymer. Another preferred embodiment of the polyalkylene glycol constituting the polymer of this disclosure is a 4- or 8-branched polyethylene glycol having a chemical structure combining a linear polyethylene glycol and a polyol, and having a number average molecular weight of 5,000 to 20,000 in the polymer. A more preferred embodiment of the polyalkylene glycol constituting the polymer of this disclosure is a 4- or 8-branched polyethylene glycol having a chemical structure combining a linear polyethylene glycol and a polyol, and having a number average molecular weight of 7,000 to 15,000 in the polymer.

[0058] Polyalkylene glycols can be manufactured using known chemical synthesis methods or are commercially available. Examples of commercially available products include the SUNBRIGHT (registered trademark) PTE series and the SUNBRIGHT (registered trademark) HGEO series (manufactured by NOFCorporation). The SUNBRIGHT (registered trademark) PTE series is a 4-branched polyethylene glycol, with a structure in which a linear polyethylene glycol chain is individually bonded to each of the four hydroxyl groups of pentaerythritol. The SUNBRIGHT (registered trademark) HGEO series is an 8-branched polyethylene glycol, with a structure in which a linear polyethylene glycol chain is individually bonded to each of the eight hydroxyl groups of polyglycerol as a glycerol tetramer.

[0059] A-2. Polyhydroxyalkanoic acid In the present disclosure, the polyhydroxyalkanoic acid constituting the polymer can be a homopolymer composed of only one monomer, or a copolymer composed of two or more monomers. When the polyhydroxyalkanoic acid is a copolymer, it can be a random copolymer or a block copolymer.

[0060] Specific examples of monomers constituting polyhydroxyalkanoates include lactic acid, glycolic acid, 6-hydroxyhexanoic acid, 3-hydroxybutyric acid, 3-hydroxyvalerate, and malic acid. Specific examples of starting monomers for generating polyhydroxyalkanoates include ε-caprolactone. The monomers constituting polyhydroxyalkanoates can be L-type or D-type, and D-type and L-type monomers can be mixed in the polymers disclosed herein. From the viewpoint of imparting excellent mechanical strength to the polymers of this disclosure, the monomers constituting polyhydroxyalkanoates are preferably composed only of D-type or L-type monomers.

[0061] Polyhydroxyalkanoic acid is preferably a homopolymer of monomers selected from lactic acid, glycolic acid, and 6-hydroxyhexanoic acid, or a copolymer containing two or more of these monomers. From the viewpoint of imparting excellent biodegradability to the polymers of this disclosure, polyhydroxyalkanoic acid is preferably a copolymer of lactic acid and glycolic acid (i.e., a lactic acid / glycolic acid copolymer), and particularly preferably a random copolymer of lactic acid and glycolic acid.

[0062] When the polyhydroxyalkanoic acid is a lactic acid / glycolic acid copolymer, the molar ratio of lactic acid in the copolymer to 1 mole of glycolic acid can be, for example, 1 to 10. From the viewpoint of biodegradability, the molar ratio of lactic acid in the copolymer to 1 mole of glycolic acid is preferably 2 to 8, more preferably 3 to 6, and particularly preferably 3 to 5. Generally, the biodegradation rate is fastest when the molar ratio of lactic acid in the copolymer to 1 mole of glycolic acid is 1, and the degradation rate decreases as the proportion of lactic acid increases.

[0063] The number-average molecular weight of the polyhydroxyalkanoic acid constituting the polymer of this disclosure is not particularly limited as long as the effects of this disclosure are achieved, and for example, it can be 8,000 to 80,000. From the viewpoint of being able to stably retain water-soluble substances in the microcapsules of this disclosure, and from the viewpoint of being able to endow the microcapsules of this disclosure with excellent sustained-release properties for water-soluble substances, the number-average molecular weight of the polyhydroxyalkanoic acid constituting the polymer of this disclosure is preferably 10,000 to 70,000, more preferably 10,000 to 60,000, and particularly preferably 10,000 to 50,000. In particular, when the polyalkylene glycol constituting the polymer of this disclosure is a branched polyalkylene glycol, the number-average molecular weight of the polyhydroxyalkanoic acid constituting the polymer of this disclosure is preferably 20,000 to 70,000, more preferably 20,000 to 60,000, even more preferably 25,000 to 55,000, and particularly preferably 30,000 to 50,000.

[0064] A preferred embodiment of the polyhydroxyalkanoic acid constituting the polymer of this disclosure is a lactic acid / glycolic acid copolymer with a number average molecular weight of 10,000 to 70,000, wherein the molar ratio of lactic acid in the lactic acid / glycolic acid copolymer to 1 mole of glycolic acid contained in the copolymer is 2 to 8. A particularly preferred embodiment of the polyhydroxyalkanoic acid constituting the polymer of this disclosure is a lactic acid / glycolic acid copolymer with a number average molecular weight of 10,000 to 60,000, wherein the molar ratio of lactic acid in the lactic acid / glycolic acid copolymer to 1 mole of glycolic acid contained in the copolymer is 3 to 6.

[0065] A-3. Structure of the polymer disclosed herein As described above, the polymer disclosed herein has a chemical structure consisting of a polyalkylene glycol and a polyhydroxyalkanoic acid. More specifically, the polymer disclosed herein has a chemical structure in which the hydroxyl groups of the polyalkylene glycol and the carboxyl groups of the polyhydroxyalkanoic acid are bonded by ester bonds.

[0066] In the polymers disclosed herein, the number of polyhydroxyalkanoic acid monomer units per polyhydroxyalkanoic acid chain can be 15 to 240. In this disclosure, the phrase "number of polyhydroxyalkanoic acid monomer units per polyhydroxyalkanoic acid chain" refers to the value obtained by dividing the total number of polyhydroxyalkanoic acid monomer units contained in the polymer by the number of terminal hydroxyl groups in the polyalkylene glycol. From the viewpoint of being able to stably retain water-soluble substances in the microcapsules of this disclosure, and from the viewpoint of being able to endow the microcapsules of this disclosure with excellent sustained-release properties for water-soluble substances, the number of polyhydroxyalkanoic acid monomer units per polyhydroxyalkanoic acid chain in the polymers disclosed herein can be 35 to 233 or 50 to 230, preferably 70 to 220, more preferably 80 to 210, even more preferably 90 to 205, and particularly preferably 100 to 200.

[0067] The ratio of the number average molecular weight of the polyalkylene glycol to the number average molecular weight of the polyhydroxyalkanoic acid in the polymer disclosed herein is not particularly limited as long as the desired effect of this disclosure is achieved; for example, it can be 1:0.5 to 1:10. From the viewpoint of being able to stably retain water-soluble substances in the microcapsules of this disclosure, and from the viewpoint of being able to endow the microcapsules of this disclosure with excellent sustained-release properties for water-soluble substances, the ratio of the number average molecular weight of the polyalkylene glycol to the number average molecular weight of the polyhydroxyalkanoic acid in the polymer disclosed herein is preferably 1:1 to 1:8, more preferably 1:2 to 1:6, and particularly preferably 1:3 to 1:5.

[0068] The number-average molecular weight of the polymer disclosed herein is not particularly limited as long as the effects of this disclosure are achieved, and for example, it can be 10,000 to 100,000. From the viewpoint of being able to stably retain water-soluble substances in the microcapsules of this disclosure, and from the viewpoint of being able to endow the microcapsules of this disclosure with excellent sustained-release properties for water-soluble substances, the number-average molecular weight of the polymer disclosed herein is preferably 10,000 to 80,000, more preferably 11,000 to 70,000, and particularly preferably 12,000 to 60,000. In particular, when the polyalkylene glycol constituting the polymer of this disclosure is a branched polyalkylene glycol, the number-average molecular weight of the polymer disclosed herein is preferably 20,000 to 80,000, more preferably 30,000 to 70,000, even more preferably 35,000 to 65,000, and particularly preferably 40,000 to 60,000.

[0069] The number-average molecular weight of the polymer, the number-average molecular weight of the polyalkylene glycol in the polymer, the number-average molecular weight of the polyhydroxyalkanoic acid in the polymer, and the molar ratio of each monomer when the polyhydroxyalkanoic acid is a copolymer can be determined by known methods. Examples of such methods include using... 1Methods for determining molecular weight by ¹H-NMR and by determining molecular weight in polystyrene or polymethyl methacrylate (PMMA) by gel permeation chromatography (GPC).

[0070] The following describes in detail the use of 1 General methods for H-NMR analysis of polymers: First, by polymers 1 The peak area of ​​each proton is calculated from the H-NMR spectrum. The peak area of ​​each proton is calculated by dividing the total peak area of ​​protons originating from a substituent by the number of protons contained in that group. In this case, the group to be selected is one whose abundance in each monomer molecule is known in advance.

[0071] Next, the number of other monomer units is calculated. The number of monomer units is calculated by dividing the total peak area of ​​protons from that monomer unit by the number of protons contained in that monomer unit, and then dividing the result by the peak area of ​​each proton calculated earlier.

[0072] Once the number of monomer units is determined, the molecular weights of the monomers that make up the polymer and the molecular weights of the parts other than the repeating parts are known, thus allowing, for example, the number-average molecular weight of the entire polymer and the number-average molecular weight of each repeating part to be calculated.

[0073] The following describes in detail the general methods for analyzing polymers using GPC: First, the polymer is dissolved in a solvent such as chloroform, and then filtered to obtain a sample solution. The sample solution is injected into a high-performance liquid chromatograph equipped with a GPC column, and separation is performed by passing the column through a temperature-controlled chamber. The results are then detected using a differential refractometer. The number-average molecular weight can be determined using a data analysis workstation or similar equipment, and can be calculated, for example, using a calibration curve derived from the relationship between the molecular weight of standard polystyrene or polymethyl methacrylate and column elution time.

[0074] The polymers disclosed herein can also be analyzed using the general analytical methods described above, or methods that are readily conceived by those skilled in the art from these general methods.

[0075] A preferred embodiment of the polymer disclosed herein is a polymer having a chemical structure combining 4- or 8-branched polyethylene glycol with a lactic acid / glycolic acid copolymer. In this polymer, the number-average molecular weight of the polyethylene glycol is preferably 3,000 to 30,000, more preferably 5,000 to 20,000, even more preferably 7,000 to 15,000, and particularly preferably 8,000 to 13,000. Furthermore, in this polymer, the number-average molecular weight of the lactic acid / glycolic acid copolymer is preferably 20,000 to 70,000, more preferably 20,000 to 60,000, even more preferably 25,000 to 55,000, and particularly preferably 30,000 to 50,000. Moreover, in this polymer, the molar ratio of lactic acid in the lactic acid / glycolic acid copolymer to the molar amount of glycolic acid in the copolymer is preferably 2 to 8, more preferably 3 to 6, and particularly preferably 3 to 5.

[0076] A preferred embodiment of the polymer disclosed herein is a polymer represented by formula (I). This polymer has a chemical structure consisting of a 4-branched polyethylene glycol copolymer combined with a lactic acid / glycolic acid copolymer.

[0077] In formula (I), k, m, n, and p are each independently a natural number from 16 to 170, preferably from 28 to 110, more preferably from 39 to 84, and even more preferably from 45 to 73. For example, when the molecular weight of the four-branched polyethylene glycol constituting the polymer is 30,000, the average value of k, m, n, and p is about 170. This value is calculated using the formula: [(30,000-132) / 44] / 4 (30,000: molecular weight of the four-branched polyethylene glycol, 132: molecular weight of the branched portion C(CH2O)4, 44: molecular weight of CH2CH2O, 4: number of branches). Similarly, when the molecular weight of the four-branched polyethylene glycol constituting the polymer is 3,000, the average value of k, m, n, and p is about 16; when the molecular weight of the four-branched polyethylene glycol constituting the polymer is 10,000, the average value of k, m, n, and p is about 56.

[0078] X 1 X 2 X 3 and X 4 Each is independently represented by a group of the following formula (II): In formula (II), s is a natural number ranging from 19 to 193, preferably from 25 to 189, and more preferably from 27 to 184. t is a natural number ranging from 3 to 115, preferably from 4 to 74, and more preferably from 5 to 55. X 1 X2 X 3 and X 4 The individual 's' can be the same as or different from each other. 1 X 2 X 3 and X 4 The individual t values ​​can be the same or different from each other. s+t can be 35 to 233, preferably 50 to 230. The portion enclosed in square brackets ([]) represents the random polymerization of the monomer units enclosed in brackets (()) (the same applies hereinafter in this specification).

[0079] Equation (II) above is more preferably expressed as Equation (III): In formula (III), v is a natural number from 9 to 97, preferably from 12 to 95, and more preferably from 13 to 92. w is a natural number from 1 to 58, preferably from 2 to 37, and more preferably from 2 to 28.

[0080] A preferred embodiment of the polymer disclosed herein is a polymer represented by the following formula (IV). When r is 4, the polymer has a chemical structure of an 8-branched polyethylene glycol copolymer combined with lactic acid / glycolic acid.

[0081] In formula (IV), k, m, n, p, and q are each independent natural numbers ranging from 7 to 84, preferably from 10 to 56, more preferably from 12 to 41, and even more preferably from 13 to 36, each time they appear. In formula (IV), r is a natural number ranging from 1 to 6. The upper or lower limit of this range can be 1, 2, 3, 4, 5, or 6.

[0082] For example, when r is 4 and the molecular weight of the 8-branched polyethylene glycol constituting the polymer is 30,000, the average value of k, m, n, p, and q is approximately 84. This value is calculated using the formula: [(30,000-454) / 44] / 8 (30,000: molecular weight of the 8-branched polyethylene glycol, 454: molecular weight of the branched portion expressed by the following formula: , 44: molecular weight of CH2CH2O, 8: number of branches) are calculated. Similarly, when r is 4 and the molecular weight of the 8-branched polyethylene glycol constituting the polymer is 3,000, the average values ​​of k, m, n, p, and q are approximately 7; when r is 4 and the molecular weight of the 8-branched polyethylene glycol constituting the polymer is 10,000, the average values ​​of k, m, n, p, and q are approximately 27.

[0083] X 1 X 2 X 3 X 4 and X5 Each group, independently and in each occurrence, is represented by the following formula (II): In formula (II), s is a natural number ranging from 10 to 96, preferably from 12 to 95, and more preferably from 14 to 92. t is a natural number ranging from 2 to 58, preferably from 2 to 37, and more preferably from 3 to 27. X 1 X 2 X 3 X 4 and X 5 The individual 's' can be the same as or different from each other. 1 X 2 X 3 X 4 and X 5 The individual t values ​​can be the same or different from each other. s+t can range from 18 to 117.

[0084] Equation (II) above is more preferably expressed as Equation (III): In formula (III), v is a natural number from 5 to 48, preferably from 6 to 48, and more preferably from 7 to 46. w is a natural number from 1 to 29, preferably from 1 to 19, and more preferably from 1 to 14.

[0085] A-4. Method for manufacturing the polymer disclosed herein Polyalkylene glycols and polyhydroxyalkanoates can be combined using conventionally known methods or methods readily conceived of by conventionally known methods. Examples include methods for polymerizing hydroxyalkanoates starting from the terminal hydroxyl groups of the polyalkylene glycol chain, and methods for combining polyalkylene glycols and polyhydroxyalkanoates via condensation reactions. More specifically, for example, the polymers disclosed herein can be obtained by ring-opening polymerization of cyclic ester intermediates of hydroxyalkanoates such as lactide using a catalyst such as stannous octoate under reduced pressure in the presence of a polyalkylene glycol. Other methods known in the art include methods for removing water, low molecular weight compounds, etc., from the reaction system by adjusting the conditions for polymerization under reflux in an organic solvent; and methods for suppressing depolymerization by deactivating the catalyst after polymerization. For example, when the resulting polymer is heat-treated under reduced pressure, unreacted cyclic ester intermediates can be removed by sublimation. More specifically, the polymers disclosed herein can be prepared, for example, according to the methods described in WO2018 / 062464 (PTL 2), or by appropriately modifying the methods described in PTL 2.

[0086] A-5. Properties of the polymers disclosed herein As described above, the total volume of the aqueous phase in the W / O (water-in-oil) emulsion prepared from the polymer of this disclosure by the following method is 0.025 cm³.3 / g~0.25cm 3 / g, as determined by differential scanning calorimetry (temperature-increasing method): 50 mg of the polymer was dissolved in 500 μL of a 0.5 w / v% sorbitan monooleate / dichloromethane solution, 100 μL of water was added, and then the mixture was sonicated to prepare a W / O emulsion. The determination of the total volume of the aqueous phase in the W / O emulsion is described in detail below.

[0087] Preparation of A-5-1. W / O Emulsion A 0.5 w / v% sorbitan monooleate / dichloromethane solution can be prepared by adding and dissolving 50 mg of sorbitan monooleate per 10 mL of dichloromethane. Sorbitan monooleate is a nonionic surfactant with an HLB of approximately 4.3. It is marketed under names such as Span (registered trademark) 80. The structure of sorbitan monooleate is shown below.

[0088] After dissolving 50 mg of the polymer to be tested in 500 μL of a 0.5 w / v% sorbitan monooleate / dichloromethane solution prepared as described above, 100 μL of water was added, and the mixture was then irradiated with ultrasound to prepare a W / O emulsion. The water used in this case was high-purity water, such as distilled water for reversed-phase chromatography (HPLC). Ultrasound was then applied to prepare the W / O emulsion. Specifically, for example, the vibrating horn of an ultrasonic homogenizer was brought into contact with the solution, and ultrasound was applied for approximately 30 seconds. The ultrasonic homogenizer used could be, for example, a Handy Sonic (UR-20P, manufactured by Tomy Seiko Co., Ltd.) or an equivalent.

[0089] A-5-2. Determination of the total volume of the aqueous phase in a W / O emulsion As described in NPL1, ice trapped in the pores has a lower melting point due to interfacial tension. Furthermore, the pores contain not only freezeable water but also non-freezing water. Since the non-freezing water exists along the pore surface, it is assumed that the amount of non-freezing water increases with decreasing pore size and increasing specific surface area. It is believed that the microenvironment inside the W / O emulsion prepared as described above is similar to the environment inside the pores described in NPL1. Therefore, it is assumed that the W / O emulsion contains ice with a lower melting point due to interfacial tension, as well as non-freezing water present along the interface with the outer oil phase.

[0090] The volume of ice with a lower melting point present in a W / O emulsion can be determined by differential scanning calorimetry (hereinafter also referred to as "DSC") as described in NPL1. In this disclosure, DSC is performed by a heating method. In this disclosure, the phrase "total volume of the aqueous phase in a W / O emulsion" refers to the volume of ice with a lower melting point present in a W / O emulsion as determined by DSC (heating method). As can be understood from the above description, the "total volume of the aqueous phase in a W / O emulsion" in this disclosure is equivalent to the volume of "freezingable porous water" described in NPL1. Furthermore, NPL 2 refers to water with a lower melting point, determined by DSC (heating method) in a similar manner to NPL1, as "frozen water clusters". Similar to the volume of "freezingable porous water" described in NPL1, the volume of "frozen water clusters" in NPL 2 is also equivalent to the "total volume of the aqueous phase in a W / O emulsion" in this disclosure.

[0091] The specific measurement conditions in differential scanning calorimetry (heating method) are not particularly limited as long as the desired effect can be obtained. For example, measurements can be performed at a heating rate of about 0.3°C / min within a measurement temperature range of about -55°C to about 5°C.

[0092] The polymer disclosed herein is characterized in that the total volume of the aqueous phase in the W / O emulsion, as determined by the above method, is 0.025 cm³. 3 / g~0.25cm 3 / g. The total volume of the aqueous phase in the W / O emulsion is calculated as the value of the components other than water contained in each gram of the sample. When using polymers with a total volume of the aqueous phase in the W / O emulsion within the above range to prepare microcapsules encapsulating polymers and water-soluble substances, microcapsules of water-soluble substances with excellent stability can be provided. The upper or lower limit of this range can be 0.025, 0.026, 0.027, 0.028, 0.029, 0.03, 0.031, 0.032, 0.033, 0.034, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. From the viewpoint of being able to stably retain water-soluble substances in the microcapsules of this disclosure, and from the viewpoint of being able to endow the microcapsules of this disclosure with excellent sustained-release properties for water-soluble substances, the total volume of the aqueous phase in the W / O emulsion of the polymer of this disclosure, as measured by the above method, is preferably 0.025 cm³. 3 / g~0.23cm 3 / g, more preferably 0.028cm3 / g~0.22cm 3 / g, preferably 0.03cm 3 / g~0.2cm 3 / g. In particular, when the polyalkylene glycol constituting the polymer of this disclosure is a branched polyalkylene glycol, the total volume of the aqueous phase in the W / O emulsion is preferably 0.025 cm³. 3 / g~0.1cm 3 / g, more preferably 0.025cm 3 / g~0.05cm 3 / g, and more preferably 0.028cm 3 / g~0.05cm 3 / g, preferably 0.03cm 3 / g~0.04cm 3 / g.

[0093] The polymer of this disclosure, possessing the aforementioned properties, can stably retain water-soluble substances within the microcapsules of this disclosure and can endow the microcapsules of this disclosure with excellent sustained-release properties for water-soluble substances. The stability of the water-soluble substances and the sustained-release properties for water-soluble substances can be evaluated using conventionally known methods or methods readily conceived by conventionally known methods. For example, when the water-soluble substance is a protein, the total protein content in the composition containing the microcapsules can be quantified using methods such as the BCA method, Bradford method, and Lowry method, and the active protein content in the composition can be quantified using methods such as ELISA. The activity retention rate (%) can then be calculated using the formula: [Active protein content / Total protein content] × 100. The sustained-release properties of the water-soluble substances can be evaluated, for example, by mixing the composition containing the microcapsules with a release test solution and quantifying the amount of water-soluble substances released into the release test solution over time.

[0094] B. This disclosure of microcapsules B-1. Definition In this disclosure, the term "microcapsule" refers to particles with an average particle size on the order of about nanometers to micrometers. To this extent, the average particle size of the microcapsules of this disclosure is not particularly limited, and may be, for example, about 10 nm to 1,000 μm, about 50 nm to 100 μm, about 100 nm to 50 μm, or about 1 μm to 10 μm. The average particle size of the microcapsules can be adjusted by conventionally known methods or by methods readily conceived by those skilled in the art. For example, the average particle size of the microcapsules can be adjusted by changing the pore size of the emulsion membrane used in preparing W / O emulsions or W / O / W emulsions. Alternatively, the average particle size of the microcapsules can be adjusted by changing the stirring speed of the stirrer used in preparing W / O emulsions or W / O / W emulsions.

[0095] In this disclosure, the average particle size refers to the average of the maximum diameters of all individual particles. Typically, the average particle size can be determined by laser diffraction scattering, dynamic light scattering, scanning electron microscopy (SEM) image analysis, sieving tests, etc. Specifically, the average particle size in this disclosure refers to the volume-based average particle size determined by laser diffraction scattering.

[0096] As described below, a preferred embodiment of the method for manufacturing the microcapsules of this disclosure is as follows: An oil phase solution containing the polymer of this disclosure and an aqueous phase solution containing a water-soluble substance are prepared separately, and then these two solutions are mixed to prepare a W / O emulsion. Each emulsion particle contained in the W / O emulsion is preferably contained within a microcapsule of this disclosure. When the W / O emulsion is dried, volatile components in the internal and external phases of the emulsion particles evaporate, resulting in a dried product containing a capsule-like structure encapsulating the water-soluble substance. The capsule-like structure in the dried product is also preferably contained within a microcapsule of this disclosure.

[0097] While not particularly limiting, in a preferred embodiment of the microcapsules disclosed herein, the polymer of this disclosure is contained within a membrane, and the water-soluble substance is encapsulated within the space surrounded by the membrane. As used herein, "membrane" refers to the portion that separates the internal and external phases of individual emulsion particles in a W / O emulsion.

[0098] B-2. Water-soluble substances There are no particular limitations on the types of water-soluble substances encapsulated in the microcapsules of this disclosure. Specific examples of water-soluble substances include low molecular weight compounds, proteins, peptides, and nucleic acids. In the techniques of this disclosure, proteins, peptides, and nucleic acids can be antibodies and / or vaccines. In this disclosure, unless otherwise stated, the term "antibody" as used alone includes antibodies and antigen-binding fragments of antibodies. Proteins and peptides can be modified with polyethylene glycol and / or sugar chains. Nucleic acids can be DNA or RNA and can be modified with protective groups or can form complexes with surfactants, lipids, polymers, etc.

[0099] Specific examples of water-soluble substances encapsulated in the microcapsules disclosed herein include parathyroid hormone (PTH), calcitonin, insulin, insulin-like growth factor, angiotensin, glucagon, GLP-1, as well as GLP-1 receptor agonist peptides represented by exendin-4, bombesin, motilin, gastrin, growth hormone, prolactin / luteotropic hormone, gonadotropin / gonadotrophic hormone, thyrotropic hormone, adrenocorticotropic hormone (ACTH), ACTH derivatives (e.g., ebiratide), melanocyte-stimulating hormone, and follicle-stimulating hormone. Hormones, including FSH, sermorelin, vasopressin, oxytocin, protirelin, luteinizing hormone (LH), corticotropin, secretin, somatropin, thyrotropin / thyroid-stimulating hormone, somatostatin, gonadotropin-releasing hormone (GnRH), G-CSF, erythropoietin (EPO), thrombopoietin (TPO), megakaryocyte potentiator, HGF, EGF, VEGF, interferon-α, interferon-β, interferon-γ, interleukins, fibroblast growth factors (FGFs), and bone morphogenetic proteins. Morphogenetic proteins (BMPs), thymic humoral factor (THF), and serum thymic factor (STMF)FTS, superoxide dismutase (SOD), urokinase, lysozyme, tissue plasminogen activator, asparaginase, kallikrein, ghrelin, adiponectin, leptin, atrial natriuretic peptide, atrial natriuretic factor, brain natriuretic peptide (BNP), conantokin-G, dynorphin, endorphin, kyotorphin, enkephalin, neurotensin, angiostatin, bradykinin, substance P P), kallidin, hemoglobin, protein C, factor VIIa, glucocerebrosidase, streptokinase, staphylokinase, thymosin, pancreozymin, cholecystokinin, human placental prolactin, tumor necrosis factor (TNF), polymyxin B, colistin, gramicidin, bacitracin, thymopoietin, bombesin, cerulein, thymostimulin, selectin, resistin, hepcidin, neuropeptide Y, neuropeptide S S), cholecystokinin-pancreozymin,CCK-PZ and brain-derived neurotrophic factor (BDNF); anti-VEGF antibodies, such as bevacizumab, faricimab, and brolucizumab; anti-VEGF antibody Fab fragments, such as ranibizumab; anti-EGFR antibodies, such as cetuximab; and vaccines.

[0100] The water-soluble substances listed above include substances that are easily decomposed, denatured, or deteriorated and lose their biological activity. According to the technology of this disclosure, even such water-soluble substances can retain their activity in the formulation. Whether a water-soluble substance retains its activity can be evaluated by conventionally known methods or methods readily conceived from conventionally known methods. For example, when the water-soluble substance is a protein, the total protein content in the formulation is quantified by methods such as the BCA method, Bradford method, and Lowry method, and the active protein content in the formulation is quantified by methods such as ELISA. The activity retention rate (%) can then be calculated using the following formula: [Active protein content / Total protein content] × 100.

[0101] B-3. ​​Method for manufacturing the microcapsules disclosed herein The microcapsules disclosed herein can be manufactured by conventional known methods or methods readily conceived from conventional known methods. Specific examples include methods such as emulsion solvent evaporation, phase separation, phase transformation, and polymer spheroidization (including spheroidization (SA) and emulsion solvent diffusion (ESD)). The solvents used can be appropriately selected according to each method.

[0102] For example, when manufacturing the microcapsules of this disclosure via emulsion solvent evaporation, after preparing an oil phase solution containing the polymer of this disclosure and an aqueous phase solution containing water-soluble substances, these two solutions can be mixed to prepare a W / O emulsion. Mixing can be performed using a magnetic stirrer, propeller stirrer, turbine stirrer, dispersion mixer, homogenizer, ultrasonic irradiator, homogenizer, membrane emulsification device equipped with a porous membrane, etc. Alternatively, the W / O emulsion can be dried to evaporate volatile components in both the internal and external phases, forming a dried product.

[0103] The oil phase solution preferably contains an aqueous immiscible organic solvent. In this disclosure, "aqueous immiscible organic solvent" refers to an organic solvent whose solubility in water is less than 30 g per 100 mL of water. The aqueous immiscible organic solvent used to manufacture the microcapsules of this disclosure preferably has a water solubility of less than 0.1 g per 100 mL of water. While not particularly limited, the aqueous immiscible organic solvent used to manufacture the microcapsules of this disclosure is preferably volatile, and more specifically, preferably a solvent that can be removed by evaporation through freeze-drying or spray drying. Specific examples of such aqueous immiscible organic solvents include ethyl acetate, isopropyl acetate, butyl acetate, dimethyl carbonate, diethyl carbonate, dichloromethane, and chloroform. Dichloromethane is particularly preferred.

[0104] The oil phase solution and the aqueous phase solution may also contain other components. For example, they may contain, alone or in combination of two or more, pharmaceutically acceptable matrices, carriers, excipients, polymers other than those disclosed in this invention, diluents, surfactants, preservatives, pH adjusters, auxiliaries, and chelating agents.

[0105] Examples of polymers other than those disclosed herein include polyalkylene glycols, polyhydroxyalkanoates, polyvinylpyrrolidone, polyvinyl alcohol, polyethyleneimine, polyacrylic acid, polymethacrylic acid, poly-1,3-dioxolane, 2-methacryloyloxyethylphosphorylcholine polymers, and poly-1,3,6-trioxane, as well as polysaccharides. Such polymers other than those disclosed herein may be used alone or in combination of two or more.

[0106] Examples of surfactants include nonionic surfactants, specifically including polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, polyoxyalkylene glycerol fatty acid esters, polyoxyalkylene fatty acid amides, polyoxyalkylene glycol fatty acid esters, polyoxyalkylene castor oil derivatives, polyoxyalkylene hydrogenated castor oil derivatives other than polyoxyalkylene hydrogenated castor oil, polyglycerol fatty acid esters, monoglycerol fatty acid esters, sorbitan fatty acid esters, sorbitan fatty acid esters, alkyl glycol fatty acid esters, alkyl polyglycosides, sugar fatty acid esters (sucrose fatty acid esters, maltose fatty acid esters, lactose fatty acid esters, etc.), fatty acid alkanolamides, and diethyl sebacate. A preferred nonionic surfactant in this disclosure is sorbitan monooleate, which is a type of sorbitan fatty acid ester. Other preferred examples include alkyl sulfates such as sodium lauryl sulfate, ammonium lauryl sulfate, and sodium stearyl sulfate, as well as lecithin and its derivatives. Surfactants can be used alone or in combination of two or more.

[0107] Examples of preservatives include methylparaben, ethylparaben, propylparaben, butylparaben and other paraben esters, sodium benzoate, phenoxyethanol, and alkyl diaminoethyl glycine hydrochloride. Preservatives can be used alone or in combination of two or more.

[0108] Examples of pH adjusters include citric acid, phosphoric acid, malic acid, pyrophosphate, lactic acid, tartaric acid, glycerophosphate, acetic acid, nitric acid, amino acids and their chemically possible salts, as well as sodium hydroxide and potassium hydroxide. In particular, L-arginine, as a basic amino acid, interacts ionicly with the polymer, increasing the encapsulation efficiency of water-soluble substances contained in the aqueous solution; therefore, it is preferred to add it to the aqueous solution. That is, L-arginine, as a basic amino acid, can not only adjust the pH of the formulation but also improve the encapsulation efficiency of water-soluble substances into microcapsules. pH adjusters can be used alone or in combination of two or more.

[0109] C. The compositions disclosed herein This disclosure also includes compositions comprising the microcapsules of this disclosure. Such compositions are also referred to as "compositions of this disclosure". Matters described with respect to the microcapsules of this disclosure are incorporated herein by reference. The compositions of this disclosure may be the microcapsules of this disclosure alone, or a mixture of the microcapsules of this disclosure with other ingredients. The miscible ingredients are not limited as long as the effects of this disclosure are achieved. Preferred examples include the ingredients described in section "B-3. Method for manufacturing the microcapsules of this disclosure". Furthermore, a W / O emulsion containing the microcapsules of this disclosure may be dispersed in another aqueous phase to form a W / O / W emulsion.

[0110] The dosage form of the disclosed compositions is not particularly limited, and may be in the form of spheres, sheets, needles, rods, or rolls. Among these dosage forms, spheres or sheets are preferred, and microspheres or films are particularly preferred. In this disclosure, the term "microsphere" refers to a spherical composition containing a polymer and a water-soluble substance and having an average particle size of about 1 to 100 μm. Furthermore, nanoparticles, microparticles, nanospheres, and microcapsules are also preferred examples of dosage forms of the disclosed compositions. The disclosed compositions are preferably sustained-release pharmaceutical compositions. In the disclosed compositions, since the water-soluble substance is encapsulated in the disclosed microcapsules, the water-soluble substance can be stably retained. Furthermore, in the disclosed compositions, since the water-soluble substance is encapsulated in the disclosed microcapsules, the disclosed compositions may have sustained-release properties for the water-soluble substance. Therefore, when the disclosed compositions are administered to a subject, it is expected that the water-soluble substance will be gradually released from the composition in the subject's body, thereby producing a sustained effect.

[0111] There are no particular limitations on the method of administering the disclosed composition to a subject, as long as the effects of this disclosure are achieved. For example, the disclosed composition may be administered directly to local sites such as the vitreous body by injection, or may be administered intravenously, intra-arterially, intra-abdominally, intramuscularly, subcutaneously, or intrapleurally by injection or infusion, or may be administered via catheter perfusion, or may be applied to the skin, mucous membranes, tissues, etc.

[0112] Examples of subjects to whom the compositions of this disclosure may be administered include humans and non-human mammals (e.g., rats, mice, rabbits, cattle, pigs, dogs, cats, sheep, and monkeys), with humans being particularly preferred.

[0113] D. Screening methods for sustained-release polymers This disclosure also includes a method for screening sustained-release polymers. The screening method includes the following steps (a) to (c): step (a), preparing a polymer solution by dissolving the polymer to be tested in a solution containing a surfactant and a water-immiscible organic solvent; step (b), adding water to the polymer solution prepared in step (a), and then irradiating it with ultrasound to prepare a W / O emulsion; and step (c), ensuring that the total volume of the aqueous phase in the W / O emulsion is 0.025 cm³ when measured by differential scanning calorimetry (temperature-increasing method). 3 / g~0.25cm 3 / g is used as an indicator to screen for sustained-release polymers. In this disclosure, this screening method is also referred to as "the screening method of this disclosure". Matters described in sections "A-1. Polyalkylene glycols" to "A-4. Methods for manufacturing polymers of this disclosure" and matters concerning water-immiscible organic solvents described in section "B-3. Methods for manufacturing microcapsules of this disclosure" are suitably incorporated by reference into the screening method of this disclosure.

[0114] There are no particular limitations on the polymers for which the screening method of this disclosure is applied. For example, it can be a polymer containing polyhydroxyalkanoic acid, preferably a polymer having a structure in which polyhydroxyalkanoic acid is combined with polyalkylene glycol.

[0115] In step (a), the polymer to be tested is dissolved in a solution containing a surfactant and an immiscible organic solvent containing water to prepare a polymer solution. The type of surfactant is not particularly limited, as long as a W / O emulsion can be prepared in step (b) below. Specific surfactants include, for example, nonionic surfactants listed in section "B-3. Method for Manufacturing Microcapsules of this Disclosure". Preferably, the surfactant has an HLB of about 2 to 7. The upper or lower limit of the HLB range can be 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7. The surfactant used in the screening method of this disclosure preferably has an HLB of about 3 to 6, more preferably about 3.5 to 5.5. A particularly preferred example of a specific surfactant is sorbitan monooleate (HLB: 4.3), which is sold under trade names such as Span (registered trademark) 80. In the screening method of this disclosure, surfactants can be used alone or in combination of two or more.

[0116] There are no particular limitations on the types of water-immiscible organic solvents used in the screening method disclosed herein. Among water-immiscible organic solvents, dichloromethane is particularly preferred.

[0117] In a solution containing a surfactant and an immiscible organic solvent, the specific amounts of the surfactant and the immiscible organic solvent are not particularly limited, provided that a W / O emulsion can be prepared in the next step (b). That is, it can be reasonably understood that the technology disclosed herein does not include embodiments where the surfactant content in the solution is extremely low or extremely high, making it impossible to prepare a W / O emulsion. As long as a W / O emulsion is prepared in the next step (b), the specific amounts of the surfactant and the immiscible organic solvent in the solution will not substantially affect the determination of the total volume of the aqueous phase within the W / O emulsion.

[0118] The solution containing the surfactant and the water-immiscible organic solvent may also contain other components, provided that the desired effect is achieved. Particularly preferred is that the solution containing the surfactant and the water-immiscible organic solvent is composed of the surfactant and the water-immiscible organic solvent. In this disclosure, the phrase "composed of..." means substantially free of other components. That is, in this disclosure, the phrase "composed of..." does not exclude the presence of unavoidable impurities.

[0119] The amount of surfactant required to prepare a W / O emulsion can be readily understood from common knowledge in the art, and / or understood by those skilled in the art through reasonable trial and error based on such common knowledge. For example, the concentration of the surfactant in an water-immiscible organic solvent can be 0.01–10 w / v%, preferably 0.1–5 w / v%, more preferably 0.2–3 w / v%, and even more preferably 0.2–3 w / v.

[0120] There is no particular limitation on the amount of the test polymer dissolved in the solution containing the surfactant and the water-immiscible organic solvent, as long as a W / O emulsion can be prepared. For example, the polymer can be dissolved in a ratio of 2 to 100 parts by mass of the solution containing the surfactant and the water-immiscible organic solvent for every 1 part by mass of the test polymer. This range is preferably 5 to 50 parts by mass, more preferably 7 to 30 parts by mass, and particularly preferably 10 to 20 parts by mass.

[0121] In step (b), water is added to the polymer solution prepared in step (a), and then ultrasonication is performed to prepare a W / O emulsion. The added water is preferably high-purity water, such as distilled water for reversed-phase chromatography (HPLC). The amount of water added is not particularly limited as long as a W / O emulsion can be prepared. For example, the amount of water added can be 0.5 to 5 parts by mass per 1 part by mass of the polymer solution. This range is preferably 1 to 4 parts by mass, and more preferably 1.5 to 3 parts by mass. As long as a W / O emulsion is prepared, the specific content of polymer and water in the W / O emulsion will not substantially affect the determination of the total volume of the aqueous phase within the W / O emulsion.

[0122] There are no particular restrictions on the conditions for ultrasonic irradiation, as long as a W / O emulsion can be prepared. For example, irradiation can be performed for about 5 seconds to 5 minutes, preferably about 10 seconds to 3 minutes, and more preferably about 15 seconds to 1 minute.

[0123] A specific method for irradiating with ultrasound is, for example, to bring the vibrating horn of an ultrasonic homogenizer into contact with the solution and apply ultrasound for approximately 30 seconds. The ultrasonic homogenizer used can be, for example, a Handy Sonic (UR-20P, manufactured by Tomy Seiko Co., Ltd.) or an equivalent device.

[0124] In step (c), the total volume of the aqueous phase in the W / O emulsion prepared as described above is determined by differential scanning calorimetry (temperature-increasing method), and the total volume of the aqueous phase in the W / O emulsion is set to 0.025 cm³. 3 / g~0.25cm 3 / g is used as an indicator for screening sustained-release polymers. Regarding the total volume of the aqueous phase in W / O emulsions, the information described in section "A-5-2. Determination of the total volume of the aqueous phase in W / O emulsions" is incorporated herein by reference.

[0125] In this disclosure, the term "sustained-release characteristic" refers to the characteristic of a water-soluble substance being continuously released from a formulation for at least one week. The term "sustained-release polymer" refers to a polymer capable of imparting a sustained-release characteristic to a water-soluble substance to a formulation prepared using the polymer. The period of continuous release of the water-soluble substance from the formulation is preferably 2 weeks or more, more preferably 3 weeks or more, even more preferably 4 weeks or more, and particularly preferably 6 weeks or more. There is no particular upper limit to this period, and it can be, for example, 6, 7, 8, 9, 10, 11, or 12 weeks or less, or 4, 5, 6, or 7 months or less. The sustained-release characteristic of the water-soluble substance can be evaluated, for example, by mixing a release test solution with the formulation and quantifying the amount of water-soluble substance released into the release test solution over time.

[0126] In this specification, the terms "comprising" and "containing" include "essentially consisting of" and "consisting of," respectively. Furthermore, this disclosure includes all combinations of any of the constituent elements described in this specification.

[0127] Furthermore, the various characteristics (properties, structures, functions, etc.) described in the embodiments of this disclosure can be combined in any manner when determining the subject matter encompassed by this invention. In other words, this disclosure includes all subject matter encompassing all combinations of the composable characteristics described in this specification. Example

[0128] The embodiments of this disclosure will now be described in more detail with reference to the examples. However, the embodiments of this disclosure are not limited to the following examples. Unless otherwise stated below, "molecular weight" refers to the average molecular weight, "PEG" refers to polyethylene glycol, and "PLGA" refers to a lactic acid / glycolic acid copolymer. Furthermore, "LA:GA" indicates the molar ratio of lactic acid monomer units to glycolic acid monomer units in the lactic acid / glycolic acid copolymer.

[0129] 1. Test 1: Determination of the total volume of the aqueous phase in a W / O emulsion First, the inventors prepared W / O emulsions using various polymers and determined the total volume of the aqueous phase in each W / O emulsion using differential scanning calorimetry (hereinafter sometimes referred to as "DSC"). Details are as follows.

[0130] 1.1 The polymers evaluated The polymers evaluated in this test are listed in the table below. Resomer RG504 (739944, LA:GA=1:1, Sigma-Aldrich) was used as PLGA (45kDa). Poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolic acid) (764760, LA:GA=1:1, Sigma-Aldrich) was used as 1PEG (2kDa)-PLGA (11.5kDa). Other polymers were prepared at LA:GA=8:2 according to the method described in WO2018 / 062464 (PTL 2).

[0131] Table 1 Polymer Name PEG portion PEG portion PLGA section Whole polymer Number of branches Molecular weight (kDa) Molecular weight (kDa) Molecular weight (kDa) PLGA (45kDa) - - 45 45 1PEG (2kDa)-PLGA (11.5kDa) linear 2 11.5 13.5 1PEG (10kDa)-PLGA (40kDa) linear 10 40 50 2PEG (10kDa)-PLGA (40kDa) 2 10 40 50 4PEG (10kDa)-PLGA (40kDa) 4 10 40 50 4PEG (10kDa)-PLGA (69kDa) 4 10 69 79 4PEG (10kDa)-PLGA (130kDa) 4 10 130 140 8PEG (10kDa)-PLGA (40kDa) 8 10 40 50 .

[0132] 1.2 Preparation of W / O Emulsion For each polymer mentioned in 1.1, a W / O emulsion was prepared using the following steps. Specifically, 50 mg of the polymer was weighed into a 2 cc spiral sample vial, and 500 μL of a 0.5 w / v% sorbitan monooleate / dichloromethane solution (labeled "oil phase solution" in the table below) was added to dissolve the polymer. After visual confirmation of dissolution, 100 μL of distilled water for reversed-phase HPLC was added, and the mixture was subjected to ultrasonic irradiation for approximately 30 seconds to prepare the W / O emulsion.

[0133] The table below shows the composition of the W / O emulsion on a weight basis.

[0134] Table 2 Added amount Weight Standard wt% polymer 50mg 50mg 6.1% <![CDATA[Oil phase solution (1.33cm 3 / g)]]> 500μL 665mg 81.6% <![CDATA[Distilled water (1cm 3 / g)]]> 100μL 100mg 12.3% .

[0135] 1.3 Determination of the total volume of the aqueous phase in W / O emulsions Within the nanoscale pores and structures, there exists ice with a lower melting point due to interfacial tension, as well as unfrozen water. DSC measurements were performed on each W / O emulsion prepared in section 1.2, and the volume of ice with a lower melting point within the W / O emulsion (i.e., the total volume of the aqueous phase within the W / O emulsion) was calculated. Detailed descriptions of the measurement methods and results are shown below.

[0136] 1.3.1 DSC Measurement Conditions DSC device: DSC Q100 (TA Instruments) Data processing: TRC-THADAP-DSC analysis program (Toray Research Center, Inc.) Measurement temperature range: approximately -55°C to 5°C Heating rate: 0.3°C / min Sample amount: approximately 5 mg Sample container: Sealed aluminum sample container Temperature / calorimetry calibration: pure water (melting point: 0.0°C, heat of fusion: 79.7 cal / g) 1.3.2 Results The table below shows the total volume of the aqueous phase in each W / O emulsion as calculated.

[0137] Table 3 Polymer Name <![CDATA[Total volume of the internal aqueous phase of the W / O emulsion (cm 3 / g)]]> PLGA (45kDa) 0.020 1PEG (2kDa)-PLGA (11.5kDa) 0.201 1PEG (10kDa)-PLGA (40kDa) 0.009 2PEG (10kDa)-PLGA (40kDa) 0.015 4PEG (10kDa)-PLGA (40kDa) 0.033 4PEG (10kDa)-PLGA (69kDa) 0.022 4PEG (10kDa)-PLGA (130kDa) 0.006 8PEG (10kDa)-PLGA (40kDa) 0.032 .

[0138] In addition, a W / O emulsion was prepared using the 4PEG (10kDa)-PLGA (40kDa) polymer listed in Table 1 according to step 1.2, except that the amount of polymer added was changed to 12.5 mg, and DSC determination was performed in the same manner. The total volume of the aqueous phase in the prepared W / O emulsion was calculated to be 0.031 cm³. 3 / g. In other words, the results show that when the same polymer is used to prepare W / O emulsions, even if the polymer content of each W / O emulsion is different, the total volume of the aqueous phase in the W / O emulsion calculated by DSC is basically the same.

[0139] 2. Test 2: Preparation of antibody-encapsulated microspheres and evaluation of their stability during production 1 Next, the inventors prepared antibody-encapsulated microspheres using a polymer whose total volume of the aqueous phase in the W / O emulsion had been determined in Test 1, and evaluated the stability of the antibodies in the microspheres during the manufacturing process. Bevacizumab (Test 2.1) and cetuximab (Test 2.2) were used as the antibodies to be encapsulated in the microspheres. Details are described below.

[0140] 2.1. Microspheres encapsulating bevacizumab 2.1.1 Preparation of microspheres 0.025 g of Span80 and 0.25 g of any of the polymers listed in Table 1 were added to 10 mL of dichloromethane and dissolved (polymer solution). 0.1 mL of a 2.5% bevacizumab solution (using bevacizumab BS 100 mg Pfizer (Pfizer Japan Inc.) for direct intravenous (IV) infusion) was added to this polymer solution, and emulsified at 20,500 rpm for 1 minute using a homogenizer. After emulsification, the mixture was spray-dried using a spray dryer (using a 1.4 mm diameter two-fluid nozzle, a nitrogen flow rate of 30 L / min, and a temperature of 10–15 °C) to obtain white granular microspheres encapsulated with bevacizumab.

[0141] Compared to microspheres obtained using the 1PEG (2kDa)-PLGA (11.5kDa) polymer, microspheres obtained using the 4PEG (10kDa)-PLGA (40kDa) polymer exhibit less adhesion between microsphere particles or to container materials, demonstrating greater flowability and thus easier handling. This suggests that microspheres obtained using the 4PEG (10kDa)-PLGA (40kDa) polymer are more useful from the perspective of reducing yield losses due to container transfer during production and improving filling accuracy into product containers.

[0142] 2.1.2 Scanning electron microscopy observation The microspheres encapsulated with bevacizumab obtained in section 2.1.1 were observed using a scanning electron microscope (JSM-IT300, JEOL Ltd.). The samples used for observation were pre-coated with palladium-gold. Images are shown below. Figures 1 to 8 .

[0143] 2.1.3 The total amount of bevacizumab was determined by MicroBCA analysis. The bevacizumab microspheres encapsulated in section 2.1.1 were dissolved in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). PBS was added to 100 μL of the resulting solution to bring the total volume to 10 mL, thus obtaining the sample solution. Additionally, bevacizumab BS 100 mg Pfizer for intravenous (IV) infusion was diluted with PBS to prepare calibration curve solutions with concentrations ranging from 0.1 to 20 μg / mL.

[0144] The total amount of bevacizumab was determined using the MicroBCA assay. 100 μL of sample solution or calibration curve solution was added to each well of a 96-well plate, along with 100 μL of working reagent prepared according to the protocol provided with the MicroBCA assay kit (Thermo Fisher Scientific). The plate was stirred for 30 seconds, followed by incubation at 37°C for 2 hours. After visual confirmation of color development, the absorbance was measured at 562 nm using a microplate reader. Table 4 shows the total amount of bevacizumab calculated from the absorbance.

[0145] 2.1.4 Determination of active bevacizumab dosage by ELISA Dissolve 5 mg of the bevacizumab-encapsulated microspheres obtained in section 2.1.1 in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). Dilute the resulting solution 1000-fold with PBS to obtain the sample solution.

[0146] In addition, bevacizumab BS 100 mg Pfizer for intravenous (IV) infusion was diluted with PBS to prepare calibration curve solutions with concentrations ranging from 2 to 200 ng / mL.

[0147] The amount of active bevacizumab was determined by ELISA. First, 100 μL of 100 ng / mL human VEGF-A165 solution was added to each well of a 96-well immunoassay plate, stirred for 1 minute, and then incubated at 37°C for 1 hour. After incubation, the liquid in each well was discarded, and washing buffer was added to each well for washing. After washing, 200 μL of 1% BSA solution was added to each well, followed by shaking at room temperature for 1 hour. After shaking, the liquid in each well was discarded, and washing buffer was added to each well for washing.

[0148] After washing, add 100 μL of sample solution or calibration curve solution to each well and shake at room temperature for 2 hours. After shaking, discard the liquid in each well and add washing buffer to each well for washing. After washing, add 100 μL of secondary antibody solution and shake at room temperature for 1 hour. After shaking, discard the secondary antibody solution and add washing buffer to each well for washing. After washing, add 100 μL of TMB ELISA substrate (high sensitivity) (Abcamplc) and shake at room temperature for 15 minutes. After visually confirming color development, add 100 μL of 1N HCl test solution (FUJIFILM Wako Pure Chemical Corporation) and measure the absorbance at 450 nm using a microplate reader. Table 4 shows the amount of active bevacizumab calculated from the absorbance. Table 4 also shows the activity retention rate (%) calculated using the following formula: [Amount of active bevacizumab / Total amount of bevacizumab] × 100.

[0149] Table 4 Polymer Name <![CDATA[Total volume (cm of the internal aqueous phase of the W / O emulsion 3 / g)]]> Total amount of bevacizumab Active bevacizumab dosage Activity retention rate (%) (μg / mg) (μg / mg) 1PEG (2kDa)-PLGA (11.5kDa) 0.201 11.8 12.5 105.9 1PEG (10kDa)-PLGA (40kDa) 0.009 23.9 10.8 45.2 2PEG (10kDa)-PLGA (40kDa) 0.015 24.6 14.0 56.8 4PEG (10kDa)-PLGA (40kDa) 0.033 15.2 14.1 92.8 4PEG (10kDa)-PLGA (69kDa) 0.022 19.2 6.3 33.0 4PEG (10kDa)-PLGA (130kDa) 0.006 17.3 2.7 15.6 8PEG (10kDa)-PLGA (40kDa) 0.032 27.0 23.6 87.5 .

[0150] 2.2. Microspheres encapsulating cetuximab 2.2.1 Preparation of microspheres 0.05 g of Span80 and 0.5 g of PLGA (45 kDa) or 4PEG (10 kDa)-PLGA (40 kDa) listed in Table 1 were added to 20 mL of dichloromethane and dissolved (polymer solution). 1 mL of 0.5% cetuximab solution (Erbitux injection 100 mg, Merck & Co., Inc.) was added to this polymer solution, and emulsified at 9500 rpm for 1 minute using a homogenizer. After emulsification, the mixture was spray-dried using a Mini Spray Dryer B-290 (BUCHI Japan Co., Ltd.) (using a 1.4 mm diameter two-fluid nozzle, nitrogen flow rate of 30 L / min, and temperature of 10–15 °C) to obtain white granular microspheres encapsulated with cetuximab.

[0151] 2.2.2 Scanning electron microscopy observation The microspheres encapsulated with cetuximab obtained in section 2.2.1 were observed using a scanning electron microscope (JSM-IT300, JEOL Ltd.). The samples used for observation were pre-coated with palladium-gold. Images are shown below. Figure 8 and Figure 9 .

[0152] 2.2.3 Total cetuximab amount determined by MicroBCA assay Dissolve 10 mg of the cetuximab microspheres obtained in section 2.2.1 in 1 mL of dimethyl sulfoxide. Add PBS to 100 μL of the resulting liquid to bring the total volume to 10 mL, thus obtaining the sample solution. Additionally, dilute 100 mg of Erbitux (registered trademark) injection with PBS to prepare calibration curve solutions with concentrations ranging from 0.1 to 10 μg / mL.

[0153] The total amount of cetuximab was determined using the MicroBCA assay. 100 μL of sample solution or calibration curve solution was added to each well of a 96-well plate, along with 100 μL of working reagent prepared according to the protocol provided with the MicroBCA assay kit (Thermo Fisher Scientific). The plate was stirred for 30 seconds, followed by incubation at 60°C for 1 hour. After visual confirmation of color development, the absorbance was measured at 562 nm using a Synergy HTX multi-mode microplate reader (BioTek Instruments, Inc.). Table 5 shows the total amount of cetuximab calculated from the absorbance.

[0154] 2.2.4 Determination of active cetuximab concentration by ELISA Dissolve 5 mg of the cetuximab microspheres obtained in section 2.2.1 in 1 mL of dimethyl sulfoxide. Add PBS to 100 μL of the resulting liquid to bring the total volume to 10 mL, thus obtaining the sample solution. Additionally, dilute 100 mg of Erbitux (registered trademark) injection with PBS to prepare calibration curve solutions with concentrations ranging from 2 to 200 ng / mL.

[0155] The amount of active cetuximab was determined by ELISA. First, 100 μL of 100 ng / mL human EGFR solution was added to a 96-well immunoassay plate (Maxi Sorp Nunc-ImmunoPlate, Thermo Fisher Scientific), stirred for 1 minute, and then incubated at 37°C for 1 hour. After incubation, the liquid in each well was discarded, and washing buffer (PBS containing 0.05% Tween 20) was added to each well for washing. After washing, 200 μL of 1% BSA solution was added to each well, followed by shaking at room temperature for 1 hour. After shaking, the liquid in each well was discarded, and washing buffer was added to each well for washing.

[0156] After washing, add 100 μL of sample solution or calibration curve solution to each well and shake at room temperature for 2 hours. After shaking, discard the liquid in each well and add washing buffer to each well for washing. After washing, add 100 μL of secondary antibody solution (goat anti-human IgG (H+L) solution) and shake at room temperature for 1 hour. After shaking, discard the secondary antibody solution and add washing buffer to each well for washing. After washing, add 100 μL of ABTS microplate peroxidase substrate (SeraCare Life Sciences, Inc.) and shake at room temperature for 15 minutes. After visually confirming color development, add 100 μL of ABTS peroxidase stop solution (SeraCare Life Sciences, Inc.) and measure the absorbance at 405 nm using a microplate reader. Table 5 shows the amount of active cetuximab calculated from the absorbance. Table 5 also shows the activity retention rate (%) calculated using the following formula: [Amount of active cetuximab / Total amount of cetuximab] × 100.

[0157] Table 5 Polymer Name <![CDATA[Total volume (cm of the internal aqueous phase of the W / O emulsion 3 / g)]]> Total amount of cetuximab Active cetuximab dosage Activity retention rate (%) (μg / mg) (μg / mg) PLGA (45kDa) 0.020 13.9 ND 0 4PEG (10kDa)-PLGA (40kDa) 0.033 12.3 10.5 84.6 .

[0158] 2.3 Summary As shown in Tables 4 and 5, when using a W / O emulsion with a total aqueous phase volume of 0.025 cm³ in the preparation of microspheres... 3 / g~0.25cm 3When using a polymer of / g as the polymer, both bevacizumab and cetuximab as the water-soluble material to be encapsulated achieved a high activity retention rate of over 80%.

[0159] These test results demonstrate that when microspheres encapsulating water-soluble substances are prepared using polymers that provide a total volume of aqueous phase within a specific range in the W / O emulsion, high stability of the water-soluble substances can be obtained.

[0160] 3. Test 3: Preparation of antibody-encapsulated microspheres and evaluation of their stability during production. For the polymers that provided excellent stability to water-soluble substances in Test 2, the inventors investigated whether a comparable, excellent level of stability to the water-soluble substances was provided even when encapsulating different water-soluble substances.

[0161] In Test 2, bevacizumab or cetuximab were used as the water-soluble material to be encapsulated in the microspheres. However, in this test, ranibizumab, fareximab, or buprofenizumab were used as the water-soluble material to be encapsulated in the microspheres. For the polymer, 4PEG (10kDa)-PLGA (40kDa) was used. As described in Test 1, the total volume of the aqueous phase in the W / O emulsion of this polymer was 0.033 cm³. 3 / g. Details are as follows.

[0162] 3.1 Evaluation using ranibizumab 3.1.1 Preparation of microspheres 0.025 g of Span80 and 0.25 g of 4PEG (10 kDa)-PLGA (40 kDa) were dissolved in 10 mL of dichloromethane (polymer solution). 0.1 mL of 0.5% ranibizumab solution (a 2-fold dilution of Lucentis (registered trademark) intravitreal injection 10 mg / mL (Novartis Pharma KK)) was added to this polymer solution, and emulsified at 20500 rpm for 1 minute using a homogenizer. After emulsification, the mixture was spray-dried using a spray dryer (using a 1.4 mm diameter two-fluid nozzle, nitrogen flow rate of 30 L / min, and temperature of 10–15 °C) to obtain white granular microspheres encapsulated with ranibizumab.

[0163] 3.1.2 Scanning electron microscopy observation The microspheres encapsulated with ranibizumab obtained in section 3.1.1 were observed using a scanning electron microscope (JSM-IT300, JEOL Ltd.). The samples used for observation were pre-coated with palladium-gold. Images are shown below. Figure 10 .

[0164] 3.1.3 Total amount of ranibizumab determined by MicroBCA analysis Dissolve 5 mg of the encapsulated ranibizumab microspheres obtained in 3.1.1 in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). Add PBS to 100 μL of the resulting liquid to bring the total volume to 10 mL, thus obtaining the sample solution. Additionally, dilute Lucentis (registered trademark) intravitreal injection solution at 10 mg / mL with PBS to prepare calibration curve solutions with concentrations ranging from 0.1 to 20 μg / mL.

[0165] The total amount of ranibizumab was determined using the MicroBCA assay. 100 μL of sample solution or calibration curve solution was added to each well of a 96-well plate, along with 100 μL of working reagent prepared according to the protocol provided with the MicroBCA assay kit (Thermo Fisher Scientific). The plate was stirred for 30 seconds, followed by incubation at 37°C for 2 hours. After visual confirmation of color development, the absorbance was measured at 562 nm using a microplate reader. Table 6 shows the total amount of ranibizumab calculated from the absorbance.

[0166] 3.1.4 Determination of active ranibizumab amount by ELISA Dissolve 5 mg of the ranibizumab-encapsulated microspheres obtained in section 3.1.1 in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). Dilute the resulting solution 1000-fold with PBS to obtain the sample solution. Additionally, dilute Lucentis (registered trademark) intravitreal injection solution at 10 mg / mL with PBS to prepare calibration curve solutions with concentrations ranging from 2 to 200 ng / mL.

[0167] The amount of active ranibizumab was determined by ELISA. First, 100 μL of 100 ng / mL human VEGF-A165 solution was added to each well of a 96-well immunoassay plate, and the plate was stirred for 1 minute with a shaker, then incubated at 37°C for 1 hour. After incubation, the liquid in each well was discarded, and washing buffer was added to each well for washing. After washing, 200 μL of 1% BSA solution was added to each well, followed by shaking at room temperature for 1 hour. After shaking, the liquid in each well was discarded, and washing buffer was added to each well for washing.

[0168] After washing, add 100 μL of sample solution or calibration curve solution to each well and shake at room temperature for 2 hours. After shaking, discard the liquid in each well and add washing buffer to each well for washing. After washing, add 100 μL of secondary antibody solution and shake at room temperature for 1 hour. After shaking, discard the secondary antibody solution and add washing buffer to each well for washing. After washing, add 100 μL of TMBELISA substrate (high sensitivity) and shake at room temperature for 15 minutes. After visually confirming color development, add 100 μL of 1N HCl test solution and measure the absorbance at 450 nm using a microplate reader. Table 6 shows the amount of active ranibizumab calculated from the absorbance. Table 6 also shows the activity retention rate (%) calculated using the following formula: [Amount of active ranibizumab / Total amount of ranibizumab] × 100.

[0169] 3.2 Evaluation using fareximab 3.2.1 Preparation of microspheres 0.025 g of Span80 and 0.25 g of 4PEG (10 kDa)-PLGA (40 kDa) were dissolved in 10 mL of dichloromethane (polymer solution). 0.1 mL of 2.4% fareximab solution (a 5-fold dilution of Vabysmo (registered trademark) intravitreal injection 120 mg / mL (Chugai Pharmaceutical Co., Ltd.)) was added to this polymer solution, and emulsified at 20,500 rpm for 1 minute using a homogenizer. After emulsification, the emulsion was spray-dried using a spray dryer (drying conditions as in 3.1.1) to obtain white granular microspheres encapsulated with fareximab.

[0170] 3.2.2 Scanning electron microscopy observation Observe the microspheres of encapsulated fareximab obtained in 3.2.1 according to 3.1.2. The observed images are shown below. Figure 11 .

[0171] 3.2.3 The total amount of fareximab was determined by MicroBCA analysis. Dissolve 5 mg of the encapsulated fareximab microspheres obtained in 3.2.1 in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). Add PBS to 100 μL of the resulting liquid to bring the total volume to 10 mL, thus obtaining the sample solution. Additionally, dilute Vabysmo (registered trademark) intravitreal injection solution at 120 mg / mL with PBS to prepare calibration curve solutions with concentrations ranging from 0.1 to 20 μg / mL. Assay was performed using the MicroBCA assay. Add 100 μL of the sample solution or calibration curve solution to each well of a 96-well plate, and add 100 μL of the working reagent prepared according to the instructions provided with the MicroBCA assay kit (Thermo Fisher Scientific). Stir the plate for 30 seconds, then incubate at 37°C for 2 hours. After visual confirmation of color development, measure the absorbance at 562 nm using a microplate reader. Table 6 shows the total amount of fareximab calculated from the absorbance.

[0172] 3.2.4 Determination of active remdesivir dosage by ELISA Dissolve 5 mg of the encapsulated fareximab microspheres obtained in 3.2.1 in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). Dilute the resulting solution 1000-fold with PBS to obtain the sample solution. Additionally, dilute Vabysmo (registered trademark) intravitreal injection solution at 120 mg / mL with PBS to prepare calibration curve solutions with concentrations ranging from 2 to 200 ng / mL.

[0173] The amount of active fareximab was determined by ELISA. First, 100 μL of 100 ng / mL human VEGF-A165 solution was added to each well of a 96-well immunoassay plate, and the plate was stirred for 1 minute with a shaker, then incubated at 37°C for 1 hour. After incubation, the liquid in each well was discarded, and washing buffer was added to each well for washing. After washing, 200 μL of 1% BSA solution was added to each well, followed by shaking at room temperature for 1 hour. After shaking, the liquid in each well was discarded, and washing buffer was added to each well for washing.

[0174] After washing, add 100 μL of sample solution or calibration curve solution to each well and shake at room temperature for 2 hours. After shaking, discard the liquid in each well and add washing buffer to each well for washing. After washing, add 100 μL of secondary antibody solution and shake at room temperature for 1 hour. After shaking, discard the secondary antibody solution and add washing buffer to each well for washing. After washing, add 100 μL of TMBELISA substrate (high sensitivity) and shake at room temperature for 15 minutes. After visually confirming color development, add 100 μL of 1N HCl test solution and measure the absorbance at 450 nm using a microplate reader. Table 6 shows the amount of active faraxicam calculated from the absorbance. Table 6 also shows the activity retention rate (%) calculated using the following formula: [Amount of active faraxicam / Total amount of faraxicam] × 100.

[0175] 3.3 Evaluation using broxol 3.3.1 Preparation of microspheres 0.025 g of Span80 and 0.25 g of 4PEG (10 kDa)-PLGA (40 kDa) were dissolved in 10 mL of dichloromethane (polymer solution). 0.1 mL of 2.4% iboxizumab solution (a 5-fold dilution of Beovu Intravitreal Injection Kit 120 mg / mL (Novartis Pharma KK)) was added to this polymer solution, and emulsified at 20,500 rpm for 1 minute using a homogenizer. After emulsification, the emulsion was spray-dried using a spray dryer (drying conditions as in 3.1.1) to obtain white granular microspheres encapsulated with iboxizumab.

[0176] 3.3.2 Scanning electron microscopy observation Observe the microspheres encapsulated with iboxizumab obtained in 3.3.1 according to 3.1.2. The observed images are shown below. Figure 12 .

[0177] 3.3.3 The total amount of iboseizumab was determined by MicroBCA analysis. Dissolve 5 mg of the encapsulated iboxizumab microspheres obtained in 3.3.1 in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). Add PBS to 100 μL of the resulting liquid to bring the total volume to 10 mL, thus obtaining the sample solution. Additionally, dilute Beovu (registered trademark) intravitreal injection kit 120 mg / mL with PBS to prepare calibration curve solutions with concentrations ranging from 0.1 to 20 μg / mL.

[0178] The total amount of iboxizumab was determined using the MicroBCA assay. 100 μL of sample solution or calibration curve solution was added to each well of a 96-well plate, along with 100 μL of working reagent prepared according to the protocol provided with the MicroBCA assay kit (ThermoFisher Scientific). The plate was stirred for 30 seconds, followed by incubation at 37°C for 2 hours. After visual confirmation of color development, the absorbance was measured at 562 nm using a microplate reader. Table 6 shows the total amount of iboxizumab calculated from the absorbance.

[0179] 3.3.4 Determination of active iborecillinumab dosage by ELISA Dissolve 5 mg of the encapsulated iboxizumab microspheres obtained in section 3.3.1 in 1 mL of a dimethyl sulfoxide / PBS mixture (7:3). Dilute the resulting solution 1000-fold with PBS to obtain the sample solution. Additionally, dilute 120 mg / mL of the Beovu (registered trademark) intravitreal injection kit with PBS to prepare calibration curve solutions with concentrations ranging from 2 to 200 ng / mL.

[0180] The amount of active iboxizumab was determined by ELISA. First, 100 μL of 100 ng / mL human VEGF-A165 solution was added to each well of a 96-well immunoassay plate, stirred for 1 minute, and then incubated at 37°C for 1 hour. After incubation, the liquid in each well was discarded, and washing buffer was added to each well for washing. After washing, 200 μL of 1% BSA solution was added to each well, followed by shaking at room temperature for 1 hour. After shaking, the liquid in each well was discarded, and washing buffer was added to each well for washing.

[0181] After washing, add 100 μL of sample solution or calibration curve solution to each well and shake at room temperature for 2 hours. After shaking, discard the liquid in each well and add washing buffer to each well for washing. After washing, add 100 μL of secondary antibody solution and shake at room temperature for 1 hour. After shaking, discard the secondary antibody solution and add washing buffer to each well for washing. After washing, add 100 μL of TMBELISA substrate (high sensitivity) and shake at room temperature for 15 minutes. After visually confirming color development, add 100 μL of 1N HCl test solution and measure the absorbance at 450 nm using a microplate reader. Table 6 shows the amount of active bloxicillin antibody calculated from the absorbance. Table 6 also shows the activity retention rate (%) calculated using the following formula: [Amount of active bloxicillin antibody / Total amount of bloxicillin antibody] × 100.

[0182] Table 6 drug Ranibizumab Faraximab broxinzylmab Total drug amount (μg / mg) 6.5 15.4 15.4 Active drug dosage (μg / mg) 5.8 13.4 11.1 Activity retention rate (%) 89.6 87.2 71.9 .

[0183] 3.4 Summary As shown in Table 6, even when ranibizumab, faraximab, or broxolizumab are used as the water-soluble material encapsulated in the microspheres, the same high activity retention rate of the water-soluble material is achieved as when bevacizumab or cetuximab are used.

[0184] The above test results show that if a polymer with a total volume of aqueous phase within a specific range is used to prepare microspheres for encapsulating water-soluble substances, high stability of the water-soluble substances can be obtained regardless of the type of water-soluble substances to be encapsulated.

[0185] 4. Test 4: Preparation of encapsulated peptide films and evaluation of their stability during production. Next, the inventors investigated encapsulating water-soluble substances in films. As polymers, 4PEG (10 kDa)-PLGA (40 kDa), 4PEG (10 kDa)-PLGA (69 kDa), or 4PEG (10 kDa)-PLGA (130 kDa), which were used in Test 1 to determine the total volume of the aqueous phase in the W / O emulsion, were employed. As the water-soluble substance, salmon calcitonin (salmon-derived calcitonin; hereinafter sometimes simply referred to as "calcitonin"), a peptide, was used. Calcitonin is a peptide composed of 32 amino acid residues (SEQ ID NO:2). The two-dimensional and three-dimensional structures of calcitonin are shown in... Figure 13 .

[0186] After preparing the film encapsulating calcitonin, the inventors extracted calcitonin from the film and determined the residual calcitonin rate using HPLC. Details are as follows.

[0187] 4.1 Preparation of films encapsulating peptides Dissolve 0.05 g of Span 80 in 10 mL of dichloromethane. Add 0.05 g of 4PEG (10 kDa)-PLGA (40 kDa), 4PEG (10 kDa)-PLGA (69 kDa), or 4PEG (10 kDa)-PLGA (130 kDa) to 0.5 mL of the resulting solution and dissolve (polymer solution). Add 100 μL of PBS (-) to 5 mg of salmon calcitonin and dissolve (aqueous phase solution). After adding the aqueous phase solution to the polymer solution, emulsify the mixture in the container by sonication for 1 minute with stirring using an ultrasonic generator (UR-20P, Tomy Seiko Co., Ltd.). Add the emulsified mixture dropwise onto a glass plate in 0.1 mL increments using a micropipette and dry to obtain a thin film.

[0188] 4.2 Peptide Extraction Add 100 μL of dichloromethane to one membrane obtained in step 4.1, followed by 250 μL of aqueous phase (1N HCl:PBS(-) = 1:3). Vortex the mixture and centrifuge to collect the supernatant. Add another 250 μL of the aqueous phase to the tube from which the supernatant was collected, stir, and centrifuge to collect the supernatant in a similar manner. Repeat this process four times for a total of four supernatant collections (i.e., a total of 1000 μL of aqueous phase added).

[0189] 4.3 Determination of peptide residual rate The residual calcitonin in the aqueous phase collected in section 4.2 was determined by HPLC. Table 7 shows the determination conditions. Table 8 shows the determined residual calcitonin levels.

[0190] Table 7 column L-column 2 ODS (250 × 3.0 mm, 3 μm) Moving phase A 0.1% trifluoroacetic acid solution Moving phase B Acetonitrile Flow rate 0.45 mL / min Column temperature 40°C Detection wavelength 220 nm Sample injection volume 20μL Scope of analysis 15min~30min .

[0191] Table 8 Polymer Name <![CDATA[Total volume of the internal aqueous phase of the W / O emulsion (cm 3 / g)]]> Calcitonin Residual Rate (%) 4PEG (10kDa)-PLGA (40kDa) 0.033 92.6 4PEG (10kDa)-PLGA (69kDa) 0.022 73.1 4PEG (10kDa)-PLGA (130kDa) 0.006 55.3 .

[0192] 4.4 Summary As shown in Table 8, when using a W / O emulsion with a total aqueous phase volume of 0.033 cm³ in the preparation of the thin film... 3 When 4PEG (10kDa)-PLGA (40kDa) was used as a polymer, a high calcitonin residue of 92.5% was obtained.

[0193] These test results demonstrate that high stability of water-soluble substances can be achieved even when they are encapsulated in films. The results also show that high stability can be obtained even when peptides with molecular weights lower than antibodies are used as water-soluble encapsulants.

[0194] 5. Test 5: Evaluation of the sustained-release properties of the antibody-encapsulated microspheres 5.1 Microspheres containing 4-branched PEG-PLGA 0.5 g of 4PEG (10 kDa)-PLGA (40 kDa), the total volume of the aqueous phase in the W / O emulsion determined in Test 1, and 0.05 g of the nonionic surfactant (Span 80) were added to 20 mL of dichloromethane and dissolved. 1 mL of 0.5% PBS solution containing human serum-derived IgG was added to the resulting polymer solution. The resulting mixture was homogenized at 9500 rpm for 1 minute to form an emulsion. The emulsified mixture was spray-dried using a Mini Spray Dryer (BUCHI Japan Co., Ltd.) to obtain white granules in a yield of 74.1%.

[0195] 5.2 In vitro release test of water-soluble substances The IgG-encapsulated microspheres obtained in step 5.1 were added to 3 mL of 1% gellan gum solution and dispersed. The entire volume of the resulting dispersion was injected into 50 mL of PBS containing 0.02% NaN3 (as a release test solution) using a 27G syringe. The resulting mixture was placed in a constant temperature bath set to 37°C to release the IgG from the microspheres.

[0196] Test solution (1 mL) was collected at each sampling time point. Test solutions containing IgG-encapsulated microspheres were collected at weeks 1, 2, 3, 4, 6, 8, and 12 after the start of the test.

[0197] 5.3 Determination of IgG Release The release of IgG in the test solution was determined using the MicroBCA method. Specifically, human serum-derived IgG was diluted with PBS to prepare calibration curve solutions with concentrations ranging from 0.1 to 20 μg / mL.

[0198] The amount of antibody in the sample solution was determined using the MicroBCA assay. Specifically, 100 μL of sample solution and calibration curve solution were added to each well of a 96-well plate, followed by 100 μL of working reagent prepared according to the MicroBCA assay kit (ThermoFisher Scientific). The plate was stirred for 30 seconds, then incubated at 60°C for 1 hour. After confirming color development, the absorbance at 562 nm was measured using a Synergy HTX multi-mode microplate reader (BioTek Instruments). The measured absorbance values ​​of the sample solution were substituted into the calibration curve to calculate the concentration of IgG in the sample solution and determine the cumulative percentage of IgG release at each time point. Figure 14 This is a graph showing the cumulative percentage of IgG release.

[0199] Figure 14 The results shown demonstrate that the microspheres according to this disclosure can release IgG over a period of approximately 3 months.

[0200] 6. Test 6: Membrane encapsulating nucleic acid 6.1 Preparation of membranes for encapsulating nucleic acids Next, the inventors attempted to encapsulate nucleic acids in a membrane. Yeast RNA was used as the nucleic acid. As the polymer, the total volume of the aqueous phase in the W / O emulsion provided in Test 1 was 0.033 cm³. 3 / g of 4PEG (10kDa)-PLGA (40kDa).

[0201] Specifically, first, 0.05 g of Span 80 was dissolved in 10 mL of dichloromethane. Then, 0.05 g of 4PEG (10 kDa)-PLGA (40 kDa) was added to 0.5 mL of the resulting solution and dissolved (polymer solution).

[0202] Furthermore, a yeast RNA solution with a concentration of 80 mg / mL was prepared using the following method. Specifically, 20 mg of yeast RNA (FUJIFILM Wako Pure Chemical Corporation) was weighed, 200 μL of PBS(-) was added and stirred, then approximately 30 μL of 1N NaOH aqueous solution was added and stirred. After confirming that the yeast RNA had dissolved, PBS(-) was added to bring the total volume to 250 μL. The pH of the prepared yeast RNA solution was approximately 5.

[0203] 25 μL of yeast RNA solution was added to the polymer solution using a micropipette. The mixture in the container was irradiated with an ultrasonic generator (US-50, Nippon Seiki Co., Ltd.) for 1 minute with stirring to emulsify it. The emulsified mixture was then added dropwise to a glass plate in 0.1 mL increments using a micropipette and dried to obtain a thin film.

[0204] 6.2 In vitro release test of water-soluble substances Place the membrane containing the nucleic acid obtained in step 6.1 into a standard vial and add 1 mL of PBS (as the release test solution). Place the standard vial in a constant temperature bath set to 37°C to allow the yeast RNA to be released from the membrane.

[0205] Stir the solution at each sampling time point and collect 1 mL of the test solution. After collecting the test solution, add 1 mL of PBS and place the bottle in a constant temperature bath set to 37°C to release the yeast RNA retained in the membrane.

[0206] 6.4 Determination of Nucleic Acid Release The amount of nucleic acid in the test solution was determined using HPLC. Table 9 shows the assay conditions. The cumulative percentage of nucleic acid released at each time point was determined. Figure 15 This is a graph showing the cumulative percentage of nucleic acids released from the membrane.

[0207] Table 9 column YMC-Pack Pro C18 AS12S03-0503WT Moving phase A 0.1M TEAA buffer (pH=7.5) Moving phase B Acetonitrile Flow rate 0.8 mL / min Column temperature 60°C Detection wavelength 260 nm Sample injection volume 50μL Scope of analysis 2 min ~ 15 min .

[0208] 7. Test 7: Preparation and sustained-release properties evaluation of W / O / W microspheres encapsulated with model dyes 7.1 W / O / W microspheres encapsulating model dyes In tests 1-6, the inventors prepared the compositions by performing a drying step after preparing the W / O emulsion. In this test, the inventors attempted to prepare W / O / W microspheres encapsulating model dyes by performing a drying step after preparing the W / O / W emulsion.

[0209] Typically, a W / O / W emulsion is prepared by first preparing a W / O emulsion and then dispersing the W / O emulsion in an aqueous phase. In this test, the inventors used a total volume of 0.033 cm³ of aqueous phase within the W / O emulsion provided in Test 1. 3 / g of 4PEG (10kDa)-PLGA (40kDa) was used as the polymer for preparing the W / O emulsion. Polyvinyl alcohol (hereinafter sometimes referred to as "PVA") was dissolved in the aqueous phase in which the W / O emulsion was to be dispersed. As a model dye, fluorescein isothiocyanate (FITC)-glucan (molecular weight: approximately 4000) was used, with a molecular weight comparable to that of a typical peptide.

[0210] Specifically, firstly, 0.5 mL of dichloromethane was added to 50 mg of 4PEG (10 kDa)-PLGA (40 kDa) and dissolved (polymer solution). Secondly, a 100 mg / mL FITC solution was prepared by dissolving 50 mg of L-arginine (Ajinomoto Co., Inc.) in 1 mL of PBS to prepare an L-arginine solution, and dissolving 5 mg of FITC-glucan (FD4, Sigma-Aldrich) in 50 μL of the L-arginine solution. Then, 50 μL of the FITC solution was added to the polymer solution, followed by stirring under ultrasonic irradiation for 30 seconds to form an emulsion (preparation of W / O emulsion).

[0211] A PVA solution containing NaCl was prepared by mixing 1 g of PVA, 1.5 g of NaCl, and 97.5 g of water with a stirring apparatus. While stirring the solution, the entire volume of the prepared W / O emulsion was added to 5 mL of the NaCl-containing PVA solution. After addition, the mixture was passed through a 5 mL syringe equipped with an emulsification connector (SPG, untreated surface, 50 μm) three times to perform SPG membrane permeation emulsification. While stirring the resulting emulsion, 10 mL of distilled water was added, and the mixture was then dried in liquid form for 3 hours (preparation of W / O / W emulsion).

[0212] The prepared W / O / W emulsion was transferred to a centrifuge tube and centrifuged at 3000 rpm for 15 minutes to collect the supernatant. Approximately 5 mL of distilled water was added to the precipitate remaining in the centrifuge tube, the mixture was stirred, and then centrifuged again in the same manner to collect the supernatant. This process was repeated three times in total. The supernatant contained 4.0% of the weight of the added model dye, resulting in an encapsulation efficiency of 94%.

[0213] The precipitate (particles) obtained after final centrifugation was collected and resuspended in 0.5 mL of 0.1 wt% mannitol aqueous solution. The resulting suspension was freeze-dried to obtain W / O / W microspheres encapsulating the model dye in 81.0% yield.

[0214] 7.2 In vitro release test of water-soluble substances Weigh 5.8 mg of the W / O / W microspheres encapsulated with the model dye obtained in section 7.1, add 1 mL of PBS (as a release test solution), and stir the mixture. Place the resulting suspension in a constant temperature bath set to 37°C to release the model dye from the microspheres.

[0215] At each sampling time point, the solution was stirred and centrifuged, and 1 mL of test solution was collected. After collecting the test solution, 1 mL of PBS was added, the mixture was stirred, and then placed in a constant temperature bath set to 37°C to release the model dye retained in the microspheres.

[0216] 7.3 Determination of model dye release The release of the model dye in the test solution was determined using a known method with a fluorescence detector. The cumulative percentage of model dye released at each time point was determined. Figure 16 This is a graph showing the cumulative percentage of dye released from the model.

[0217] 8. Test 8: Preparation of W / O / W microspheres encapsulated with nucleic acids, evaluation of sustained-release properties and stabilization 8.1 Preparation of W / O / W microspheres encapsulating nucleic acids The W / O / W emulsion was prepared using the same procedure as in Test 7. In this test, the inventors used a total aqueous phase volume of 0.033 cm³ in the W / O emulsion provided in Test 1. 3 / g of 4PEG (10kDa)-PLGA (40kDa) was used as the polymer for preparing the W / O emulsion. As the nucleic acid, siRNA compound 1 with the following structure was used.

[0218] siRNA compound 1 The siRNA consisting of the nucleotide sequence shown in SEQ ID NO:1 (where P represents a proline derivative linker represented by the following formula): Specifically, firstly, 5 mL of dichloromethane was added to 500 mg of 4PEG (10 kDa)-PLGA (40 kDa) and dissolved (polymer solution). Secondly, a 100 mg / mL siRNA compound 1 solution was prepared by dissolving 1 g of L-arginine (Ajinomoto Co., Inc.) in 20 mL of PBS to prepare an L-arginine solution, and then dissolving 100 mg of siRNA compound 1 in 1 mL of the L-arginine solution. Then, 500 μL of the siRNA compound 1 solution was added to the polymer solution, followed by stirring under ultrasonic irradiation for 30 seconds to form an emulsion (preparation of W / O emulsion).

[0219] A PVA solution containing NaCl was prepared by mixing 1 g of PVA, 1.5 g of NaCl, and 97.5 g of water with stirring. While stirring the solution, the entire volume of the prepared W / O emulsion was added to 50 mL of the NaCl-containing PVA solution. After addition, the mixture was passed back and forth three times through an emulsion membrane (SPG, untreated surface, pore size: 50 μm) using a syringe. While stirring the resulting emulsion, 100 mL of distilled water was added, and the mixture was then dried in liquid form for 3 hours (preparation of a W / O / W emulsion with an average particle size of 8 μm).

[0220] A PVA solution containing NaCl was prepared by mixing 1 g of PVA, 1.5 g of NaCl, and 97.5 g of water. While stirring the solution, the entire volume of the prepared W / O emulsion was added to 50 mL of the NaCl-containing PVA solution. After addition, the mixture was ultrasonically irradiated for 30 seconds, and then passed through an emulsion membrane (SPG, untreated surface, pore size: 5 μm) three times using a syringe. While stirring the resulting emulsion, 100 mL of distilled water was added, and the mixture was then dried in liquid form for 3 hours (preparation of a W / O / W emulsion with an average particle size of 3 μm).

[0221] For comparison, except that the polymer was changed from 4PEG (10kDa)-PLGA (40kDa) to provide a total volume of 0.020 cm³ of aqueous phase in the W / O emulsion in Test 1. 3Except for PLGA (45 kDa) per g, W / O / W emulsions were prepared using the same procedure as those used for preparing W / O / W emulsions with an average particle size of 3 μm.

[0222] The prepared W / O / W emulsion was centrifuged at 3000 rpm for 15 minutes, and the supernatant was collected. Approximately 50 mL of distilled water was added to the remaining precipitate, the mixture was stirred, and then centrifuged again in the same manner to collect the supernatant. This operation was repeated three times in total. 5 mL of a 0.1% mannitol aqueous solution was added to the resulting W / O / W emulsion to redisperse it, followed by freeze-drying to prepare microspheres. Figure 17 SEM images of the prepared microspheres are shown.

[0223] 8.2 Evaluation of drug encapsulation efficiency and activity retention of microspheres encapsulating siRNA compound 1 Weigh 5.8 mg of each of the microspheres prepared in Test 8.1, dissolve them in 1 mL of DMSO in an Eppendorf tube, dilute the resulting solution 100-fold, and perform high-performance liquid chromatography (HPLC) under the following conditions. Drug encapsulation efficiency was calculated using the formula: [Amount of drug in microspheres / Amount of drug added] × 100. Activity retention was calculated using the formula: [Peak area of ​​unchanged form / Total peak area of ​​related substances] × 100.

[0224] HPLC determination conditions Column: ACQUITY UPLC oligonucleotide BEH C18 column (size: 4.6 mm ID × 5 cm) Mobile phase A: 50 mmol / L TEAA, 2 mmol / L EDTA (pH=7.5) Mobile phase B: Solution A / acetonitrile (30 / 70) Flow rate: 0.8 mL / min Column temperature: 40°C Injection volume: 50 μL Detection wavelength: 260 nm Analysis time: 15 minutes Gradient condition: Table 10 Time (min) B% 0 5 6 35 6.1 100 9 100 9.1 5 15 5 .

[0225] The results are shown in the table below.

[0226] Table 11 PLGA (45 kDa) 4PEG (10 kDa)-PLGA (40 kDa) 4PEG (10 kDa)-PLGA (40 kDa) <![CDATA[Total volume of the internal aqueous phase of the W / O emulsion (cm 3 / g)]]> 0.02 0.033 0.033 Emulsion membrane pore size 5μm 5μm 50μm Particle size (μm) 3 3 8.1 Encapsulation efficiency (%) of siRNA compound 1 30.9 67.6 87.7 Activity retention rate (%) 96.3 100 100 .

[0227] When using the W / O emulsion provided in Test 1, the total volume of the aqueous phase was 0.020 cm³. 3 When microspheres were prepared using PLGA (45 kDa) at a concentration of / g, the activity retention decreased to 96.3%, and the drug encapsulation efficiency was 30.9%. On the other hand, when the total volume of the aqueous phase in the W / O emulsion provided in Test 1 was 0.033 cm³, the effect was less pronounced. 3 When preparing microspheres from 4PEG (10kDa)-PLGA (40kDa) at a concentration of 1 / g, the activity retention rate was 100% under all conditions, and the drug encapsulation efficiency was 67.6% and 87.7%, respectively. The particle size of the microspheres can be controlled by using emulsion membranes with different pore sizes to prepare W / O / W emulsions.

[0228] 8.3 Evaluation of the drug release capability of microspheres encapsulating siRNA compound 1 Weigh 5.8 mg of each of the microspheres prepared in Test 8.1, add 1 mL of PBS, stir the mixture, and let it stand at 37°C. After a predetermined time, sample and centrifuge; then, take the entire volume (approximately 1 mL) of the supernatant containing the released drug and calculate the release percentage and activity retention rate of siRNA compound 1. Add 1 mL of PBS to the precipitated microspheres, stir the mixture, and let it stand at 37°C. Repeat this operation. The release percentage is calculated using the formula: [Cumulative drug release / Drug amount in microspheres] × 100. The effective sustained-release rate is calculated using the formula: [(Release amount at the final time point - Initial burst (1-hour time point) release amount) / Drug amount in microspheres] × 100. The effective sustained-release rate in the unchanged form is calculated using the formula: [(Sum of release amounts at each time point × Activity retention rate) / Drug amount in microspheres] × 100.

[0229] The results are shown in the table below and Figure 18 .

[0230] Table 12 PLGA (45 kDa) 4PEG (10 kDa)-PLGA (40 kDa) 4PEG (10 kDa)-PLGA (40 kDa) <![CDATA[Total volume of the internal aqueous phase of the W / O emulsion (cm 3 / g)]]> 0.02 0.033 0.033 Particle size (μm) 3 3 8.1 Effective sustained release rate 15.4 88.6 90.4 Effective sustained release rate in unchanged form 10.8 78.6 66.4 .

[0231] Based on this study, it was confirmed that when siRNA compound 1 was encapsulated in the W / O emulsion provided in Test 1, the total volume of the aqueous phase was 0.033 cm³. 3 When microspheres are obtained by using 4PEG (10kDa)-PLGA (40kDa) as a polymer, the initial burst release is low, and the drug is released while maintaining its activity over a long period of time.

[0232] 8.4. Evaluation of the stability of microspheres encapsulating siRNA compound 1 against RNA-degrading enzymes Weigh 5.8 mg of microspheres (particle size: 3 μm or 8 μm) prepared using 4PEG (10 kDa)-PLGA (40 kDa) as the polymer in Test 8.1. Add 0.5 mL of buffer solution and stir the mixture. Add 0.5 mL of 0.5 μg / mL RNases solution to the resulting mixture, stir, and incubate at 37°C. After a predetermined time, collect the sample, stir, and then centrifuge. Wash the precipitated microspheres and calculate the activity retention of the drug encapsulated in the microspheres. Additionally, add 0.5 mL of 0.5 μg / mL RNases solution to 0.5 mL of 0.5 mg / mL siRNA compound 1 solution diluted with buffer, stir the mixture, and incubate at 37°C. Calculate the activity retention after a predetermined time.

[0233] The results are shown in Figure 19 In aqueous solution, without encapsulation in microspheres, siRNA compound 1 was rapidly degraded by RNases. On the other hand, when encapsulated in the W / O emulsion provided in Test 1, the total volume of the aqueous phase was 0.033 cm³. 3 When microspheres are obtained by using 4PEG (10kDa)-PLGA (40kDa) as a polymer, the drug activity retention rate in the microspheres is over 80% over a long period of up to three months.

[0234] 9. Summary of Implementation Examples The results of tests 1-4 and 8 demonstrate that if microcapsules encapsulating water-soluble substances are prepared using polymers whose total volume of the aqueous phase in the W / O emulsion, as measured by the methods disclosed herein, is within a specific range, high stability of the water-soluble substances can be achieved regardless of the type of water-soluble substance to be encapsulated. The results also demonstrate that compositions containing these microcapsules exhibit high stability of the water-soluble substances regardless of the dosage form (e.g., microspheres or films).

[0235] Furthermore, the results of tests 5–7 indicate that the composition containing microcapsules not only exhibits stability to water-soluble substances but also demonstrates sustained-release properties. These results prove that sustained-release properties can be exhibited regardless of whether the water-soluble substance to be encapsulated is a protein, nucleic acid, or peptide.

[0236] Therefore, the above embodiments demonstrate that the technology disclosed herein can provide formulations of water-soluble substances with excellent stability, and the formulations can also have sustained-release properties for water-soluble substances.

Claims

1. Microcapsules comprising a polymer having a chemical structure of polyalkylene glycols and polyhydroxyalkanoates, and a water-soluble substance; When the polymer was measured by differential scanning calorimetry (temperature-increasing method) on a W / O emulsion prepared according to the following method, the total volume of the aqueous phase in the W / O emulsion was 0.025 cm³. 3 / g~0.25cm 3 / g, Method: This method involves dissolving 50 mg of the polymer in 500 μL of a 0.5 w / v% sorbitan monooleate / dichloromethane solution, adding 100 μL of water, and then irradiating with ultrasound to prepare a W / O emulsion.

2. The microcapsule according to claim 1, wherein, The polyhydroxyalkanoic acid is a homopolymer of monomers selected from lactic acid, glycolic acid and 6-hydroxyhexanoic acid, or a copolymer containing two or more of the monomers.

3. The microcapsule according to claim 1 or 2, wherein, The polyalkylene glycol has a chemical structure consisting of a linear polyalkylene glycol and a polyol, and each molecule has 3 to 10 terminal hydroxyl groups.

4. The microcapsule according to claim 1 or 2, wherein, The polyalkylene glycol is a 4- or 8-branched polyethylene glycol.

5. The microcapsule according to claim 1 or 2, wherein, The number-average molecular weight ratio of the polyalkylene glycol to the polyhydroxyalkanoic acid is 1:1 to 1:

6.

6. The microcapsule according to claim 1 or 2, wherein, The water-soluble substance is selected from at least one of proteins, peptides, and nucleic acids.

7. A composition comprising the microcapsules of claim 1 or 2.

8. A screening method for sustained-release polymers, comprising the following steps (a) to (c), Step (a): The step of preparing the polymer solution by dissolving the polymer to be tested in a solution containing a surfactant and an immiscible organic solvent containing water. Step (b): A W / O emulsion is prepared by adding water to the polymer solution prepared in step (a) and then irradiating it with ultrasound. Step (c): The total volume of the aqueous phase in the W / O emulsion prepared in step (b) is 0.025 cm³ when measured by differential scanning calorimetry (temperature-increasing method). 3 / g~0.25cm 3 The step of screening sustained-release polymers using / g as an indicator.

Citation Information

Patent Citations

  • Anti-conglutination material

    WO2018062464A1